uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.933 | Q17 | What gene does the drug Clomipramine Hydrochloride target? | The drug Clomipramine Hydrochloride targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clomipramine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%clomipramine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%clomipramine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1137', 'drugName': 'Clomipramine Hydrochloride', 'tradeNames_string': 'Anafranil, Anafranil sr, Chlorimipramine, Clomipramine hydrochloride, Tranquax', 'drugSynonyms_string': 'Clomipramine hcl, Clomipramine hydrochloride, G 34586, G-34586, NSC-759323', 'linkedDiseasesDrug_string': 'Obsessive-Compulsive Disorder (EFO_0004242), Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.159 | Q17 | What gene does the drug Minoxidil target? | The drug Minoxidil targets 2 genes: KCNJ11 and ABCC9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%minoxidil%" OR LOWER(tradeNames_string) LIKE "%minoxidil%" OR LOWER(drugSynonyms_string) LIKE "%minoxidil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5982', 'drugName': 'Minoxidil', 'tradeNames_string': "Loniten, Lonolox, Men's rogaine, Minodyl, Minoxidil, Minoxidil (for men), Minoxidil (for women), Minoxidil extra strength (for men), Regaine for men, Regaine for women, Rogaine, Rogaine (for men), Rogaine (for women), Rogaine extra strength (for men), Theroxidil, Women's rogaine", 'drugSynonyms_string': 'Alopexil, Alostil, Minoxidil, Minoximen, Mintop, NSC-757106, Normoxidil, Pierminox, Prexidil, Tricoxidil, U-10,858, U-10858', 'linkedDiseasesDrug_string': 'Androgenetic Alopecia (EFO_0004191), Alopecia (MONDO_0004907), Hypotrichosis (MONDO_0003037), Hypertension (EFO_0000537), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC9 (ENSG00000069431)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.425 | Q17 | What gene does the drug Linaclotide target? | The drug Linaclotide targets the gene GUCY2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%linaclotide%" OR LOWER(tradeNames_string) LIKE "%linaclotide%" OR LOWER(drugSynonyms_string) LIKE "%linaclotide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5063', 'drugName': 'Linaclotide', 'tradeNames_string': 'Constella, Linzess', 'drugSynonyms_string': 'ASP-0456, ASP0456, Linaclotide, MD-1100', 'linkedDiseasesDrug_string': 'Colorectal Adenoma (EFO_0005406), Constipation (HP_0002019), Constipation Disorder (MONDO_0002203), Irritable Bowel Syndrome (EFO_0000555), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY2C (ENSG00000070019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1804 | Q17 | What gene does the drug Oxymetazoline target? | The drug Oxymetazoline targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxymetazoline%" OR LOWER(tradeNames_string) LIKE "%oxymetazoline%" OR LOWER(drugSynonyms_string) LIKE "%oxymetazoline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_543', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_string': 'Afrazine, Ocuclear, Rhofade, Upneeq, Visine, Visine l.r.', 'drugSynonyms_string': 'Agn-199201, NSC-757254, Oximetazoline hydrochloride, Oxymetazoline hcl, Oxymetazoline hydrochloride, SCH 9384, SCH-9384', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Rosacea (EFO_1000760), Common Cold (EFO_0007214), Presbyopia (MONDO_0001330), Seasonal Allergic Rhinitis (EFO_0003956), Erythema (HP_0010783), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Ptosis (MONDO_0000728)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_103', 'drugName': 'Oxymetazoline', 'tradeNames_string': '', 'drugSynonyms_string': 'Nasacon, Ocuclear, Operil, Oxymetazoline', 'linkedDiseasesDrug_string': 'Fecal Incontinence (EFO_0009523), Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Orthostatic Hypotension (EFO_0005252), Common Cold (EFO_0007214), Rosacea (EFO_1000760), Presbyopia (MONDO_0001330), Seasonal Allergic Rhinitis (EFO_0003956), Erythema (HP_0010783), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Eye Allergy (EFO_0005751), Ptosis (MONDO_0000728)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.483 | Q17 | What gene does the drug Rotigotine target? | The drug Rotigotine targets 3 genes: DRD3, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rotigotine%" OR LOWER(tradeNames_string) LIKE "%rotigotine%" OR LOWER(drugSynonyms_string) LIKE "%rotigotine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2304', 'drugName': 'Rotigotine', 'tradeNames_string': 'Neupro', 'drugSynonyms_string': 'Leganto, Rotigotine, SPM 962, SPM-962', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Stroke (EFO_0000712), Parkinson Disease (MONDO_0005180), Fibromyalgia (EFO_0005687), Restless Legs Syndrome (EFO_0004270)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1512 | Q17 | What gene does the drug Lutikizumab target? | The drug Lutikizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: IL1A and IL1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lutikizumab%" OR LOWER(tradeNames_string) LIKE "%lutikizumab%" OR LOWER(drugSynonyms_string) LIKE "%lutikizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_573', 'drugName': 'Lutikizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'A-1234138, ABT-981, Abt-981, Lutikizumab', 'linkedDiseasesDrug_string': 'Hidradenitis Suppurativa (EFO_1000710), Osteoarthritis (MONDO_0005178)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL1A (ENSG00000115008), IL1B (ENSG00000125538)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_574', 'drugName': 'Lutikizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'A-1234138, ABT-981, Abt-981, Lutikizumab', 'linkedDiseasesDrug_string': 'Hidradenitis Suppurativa (EFO_1000710), Osteoarthritis (MONDO_0005178)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL1A (ENSG00000115008), IL1B (ENSG00000125538)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.675 | Q17 | What gene does the drug Spesolimab target? | The drug Spesolimab targets 2 genes: IL1RL2 and IL1RAP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%spesolimab%" OR LOWER(tradeNames_string) LIKE "%spesolimab%" OR LOWER(drugSynonyms_string) LIKE "%spesolimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2421', 'drugName': 'Spesolimab', 'tradeNames_string': 'Spevigo', 'drugSynonyms_string': 'BI 655130, BI-655130, BI655130, Bi655130, Spesolimab, Spesolimab-sbzo', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Pustulosis Palmaris Et Plantaris (MONDO_0015597), Crohn'S Disease (EFO_0000384), Atopic Eczema (EFO_0000274), Ulcerative Colitis (EFO_0000729), Hidradenitis Suppurativa (EFO_1000710), Immune System Disease (EFO_0000540)", 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL1RL2 (ENSG00000115598), IL1RAP (ENSG00000196083)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1238 | Q17 | What gene does the drug Cyclosporine target? | The drug Cyclosporine targets the gene PPIA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cyclosporine%" OR LOWER(tradeNames_string) LIKE "%cyclosporine%" OR LOWER(drugSynonyms_string) LIKE "%cyclosporine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1993', 'drugName': 'Cyclosporine', 'tradeNames_string': 'Capimune, Capsorin, Cequa, Cyclosporine, Deximune, Gengraf, Ikervis, Neoral, Optimmune, Restasis, Restasis multidose, Sandimmun, Sandimmune, Sangcya, Vanquoral, Verkazia', 'drugSynonyms_string': '27-400, ANTIBIOTIC S-7481F1, Atopica, Ciclosporin, Ciclosporin a, Ciclosporinum, Cyclosporin, Cyclosporin a, Cyclosporine, Cyclosporine a, Cyclosporine microemulsion, Cyclosporine, modified, Equoral, Mitogard, NSC-290193, Neoplanta, Neurostat, OL-27-400, Ramihyphin a, SANG-35, SDZ-OXL-400, Zinograf me', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Skin Cancer (MONDO_0002898), Liver Disease (EFO_0001421), Behcet'S Syndrome (EFO_0003780), Hemophagocytic Syndrome (MONDO_0015540), Lung Disease (EFO_0003818), Bronchiolitis Obliterans (EFO_0007183), Lymphoid Neoplasm (EFO_0001642), Atopic Eczema (EFO_0000274), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myocardial Infarction (EFO_0008583), Aplastic Anemia (HP_0001915), Retinoblastoma (MONDO_0008380), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Tropical Spastic Paraparesis (EFO_0007527), Sickle Cell Anemia (MONDO_0011382), Aspergillosis (EFO_0007157), Brain Neoplasm (EFO_0003833), Venous Thromboembolism (EFO_0004286), Myositis (EFO_0000783), Pterygium (EFO_0000678), Heart Disease (EFO_0003777), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Systemic Inflammatory Response Syndrome (EFO_1001478), Lymphoma, Aids-Related (EFO_1001365), Interstitial Cystitis (EFO_0008507), Colorectal Adenocarcinoma (EFO_0000365), Autoimmune Hepatitis (EFO_0005676), Kidney Disease (EFO_0003086), Acute Kidney Injury (HP_0001919), Epidermolysis Bullosa (EFO_1000690), Myocarditis (EFO_0009609), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Lupus Nephritis (EFO_0005761), Hereditary Angioedema (MONDO_0019623), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Juvenile Dermatomyositis (EFO_0000557), Neuroepithelial Neoplasm (MONDO_0021193), Pure Red-Cell Aplasia (MONDO_0001705), Leber Hereditary Optic Neuropathy (MONDO_0010788), Abdominal Aortic Aneurysm (EFO_0004214), Familial Lipoprotein Lipase Deficiency (MONDO_0009387), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Urticaria (EFO_0005531), Uveitis (EFO_1001231), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Beta-Thalassemia (Orphanet_848), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Granulomatous Disease (MONDO_0018305), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Allergic Conjunctivitis (EFO_0007141), Retinal Vasculitis (EFO_1001156), Severe Aplastic Anemia (EFO_0006927), Anemia, Hemolytic, Autoimmune (EFO_1001264), Chronic Hepatitis C Virus Infection (EFO_0004220), Keratoconjunctivitis (MONDO_0004768), Hodgkins Lymphoma (EFO_0000183), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Diabetes Mellitus (EFO_0000400), Neuroblastoma (EFO_0000621), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Eye Disease (EFO_0003966), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Mast-Cell Leukemia (EFO_0007359), Glaucoma (MONDO_0005041), Mucopolysaccharidosis (MONDO_0019249), Focal Segmental Glomerulosclerosis (EFO_0004236), Leprosy (EFO_0001054), Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Epiphora (HP_0009926), Periodontitis (EFO_0000649), Mycosis Fungoides (EFO_1001051), B-Cell Prolymphocytic Leukemia (EFO_1000102), 22Q11.2 Deletion Syndrome (MONDO_0018923), Respiratory Syncytial Virus Infection (EFO_1001413), Chronic Obstructive Pulmonary Disease (EFO_0000341), Myocardial Infarction (EFO_0000612), Waldenstrom Macroglobulinemia (EFO_0009441), Brain Injury (MONDO_0043510), Cutaneous Melanoma (EFO_0000389), Osteogenesis Imperfecta (MONDO_0019019), Chronic Myeloproliferative Disorder (EFO_0002428), Eczema (HP_0000964), Neoplasm (EFO_0000616), T-Cell Prolymphocytic Leukemia (EFO_1000560), Primary Membranoproliferative Glomerulonephritis (MONDO_0018904), Sarcoma (EFO_0000691), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Kidney Failure (EFO_1002048), Dry Eye Syndrome (EFO_1000906), Burkitts Lymphoma (EFO_0000309), Stevens-Johnson Syndrome (EFO_0004276), Chronic Myelogenous Leukemia (EFO_0000339), Hepatitis C Virus Infection (EFO_0003047), Familial Atrioventricular Septal Defect (MONDO_0020290), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Membranous Glomerulonephritis (EFO_0004254), Cardiac Arrest (EFO_0009492), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Fallopian Tube Cancer (MONDO_0002158), Ischemia Reperfusion Injury (EFO_0002687), Kidney Cancer (MONDO_0002367), Severe Acute Respiratory Syndrome (EFO_0000694)", 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPIA (ENSG00000196262)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1873 | Q17 | What gene does the drug Chlordiazepoxide target? | The drug Chlordiazepoxide targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlordiazepoxide%" OR LOWER(tradeNames_string) LIKE "%chlordiazepoxide%" OR LOWER(drugSynonyms_string) LIKE "%chlordiazepoxide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4453', 'drugName': 'Chlordiazepoxide', 'tradeNames_string': 'Clopoxide, Librelease, Libritabs, Librium, Sarlib, Trakipeal, Zeisin', 'drugSynonyms_string': 'A-Poxide, Chlordiazachel, Chlordiazepoxide, Chlordiazepoxide civ, Clopoxide, Librium, Lygen', 'linkedDiseasesDrug_string': 'Anxiety Disorder (EFO_0006788), Anxiety (EFO_0005230), Major Depressive Disorder (MONDO_0002009), Alcohol Withdrawal (EFO_0004777), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_2854', 'drugName': 'Chlordiazepoxide Hydrochloride', 'tradeNames_string': 'A-poxide, Chlordiazachel, Chlordiazepoxide hydrochloride, Librium, Lygen, Tropium', 'drugSynonyms_string': 'Chlordiazepoxide hcl, Chlordiazepoxide hydrochloride, Clopoxide chloride, NSC-115748, RO 5-0690, RO-5-0690', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1299 | Q17 | What gene does the drug Evt-101 target? | The drug Evt-101 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: GRIN1 and GRIN2B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%evt-101%" OR LOWER(tradeNames_string) LIKE "%evt-101%" OR LOWER(drugSynonyms_string) LIKE "%evt-101%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2903', 'drugName': 'Evt-101', 'tradeNames_string': '', 'drugSynonyms_string': '', 'linkedDiseasesDrug_string': 'Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2B (ENSG00000273079)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3345', 'drugName': 'Evt-101', 'tradeNames_string': '', 'drugSynonyms_string': 'Evt-101, Evt101', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2B (ENSG00000273079)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.453 | Q17 | What gene does the drug Abaloparatide target? | The drug Abaloparatide targets the gene PTH1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abaloparatide%" OR LOWER(tradeNames_string) LIKE "%abaloparatide%" OR LOWER(drugSynonyms_string) LIKE "%abaloparatide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1895', 'drugName': 'Abaloparatide', 'tradeNames_string': 'Tymlos', 'drugSynonyms_string': 'Abaloparatide, BA-058, BA058, BIM-44058', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Bone Fracture (EFO_0003931), Postmenopausal Osteoporosis (EFO_0003854)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.559 | Q17 | What gene does the drug Mobocertinib Succinate target? | The drug Mobocertinib Succinate targets the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mobocertinib succinate%" OR LOWER(tradeNames_string) LIKE "%mobocertinib succinate%" OR LOWER(drugSynonyms_string) LIKE "%mobocertinib succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1983', 'drugName': 'Mobocertinib Succinate', 'tradeNames_string': 'Exkivity', 'drugSynonyms_string': 'Mobocertinib succinate', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.181 | Q17 | What gene does the drug Picotamide target? | The drug Picotamide targets 2 genes: TBXA2R and TBXAS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%picotamide%" OR LOWER(tradeNames_string) LIKE "%picotamide%" OR LOWER(drugSynonyms_string) LIKE "%picotamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4429', 'drugName': 'Picotamide', 'tradeNames_string': '', 'drugSynonyms_string': 'G-137, NSC-304384, Picotamide', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4430', 'drugName': 'Picotamide', 'tradeNames_string': '', 'drugSynonyms_string': 'G-137, NSC-304384, Picotamide', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.396 | Q17 | What gene does the drug Cyclizine Lactate target? | The drug Cyclizine Lactate targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cyclizine lactate%" OR LOWER(tradeNames_string) LIKE "%cyclizine lactate%" OR LOWER(drugSynonyms_string) LIKE "%cyclizine lactate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_954', 'drugName': 'Cyclizine Lactate', 'tradeNames_string': 'Marezine', 'drugSynonyms_string': 'Cyclizine lactate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.584 | Q17 | What gene does the drug Pioglitazone target? | The drug Pioglitazone targets the gene PPARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pioglitazone%" OR LOWER(tradeNames_string) LIKE "%pioglitazone%" OR LOWER(drugSynonyms_string) LIKE "%pioglitazone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_878', 'drugName': 'Pioglitazone Hydrochloride', 'tradeNames_string': 'Actos, Diabiom, Glidipion, Glizofar, Pioglitazone hydrochloride', 'drugSynonyms_string': 'Actos, NSC-758876, Pioglitazone (as hydrochloride), Pioglitazone hcl, Pioglitazone hydrochloride, Piomed, STR-001, U-72107A', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Chronic Kidney Disease (EFO_0003884), Oral Leukoplakia (HP_0002745), Amyotrophic Lateral Sclerosis (MONDO_0004976), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Major Depressive Disorder (MONDO_0002009), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1041', 'drugName': 'Pioglitazone', 'tradeNames_string': '', 'drugSynonyms_string': 'AD-4833, Actos, Duetact, Glustin, Pioglitazone, U-72107, Zactos', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Psoriasis (EFO_0000676), Alzheimer Disease (MONDO_0004975), Multiple Myeloma (EFO_0001378), Coronary Artery Disease (EFO_0001645), Infection (EFO_0000544), Friedreich Ataxia (MONDO_0100339), Multiple Sclerosis (MONDO_0005301), Peripheral Arterial Disease (EFO_0004265), Liver Disease (EFO_0001421), Obesity (EFO_0001073), Pulmonary Arterial Hypertension (EFO_0001361), Squamous Cell Lung Carcinoma (EFO_0000708), Systemic Lupus Erythematosus (MONDO_0007915), Gastroparesis (EFO_1000948), Chronic Myelogenous Leukemia (EFO_0000339), Hepatitis C Virus Infection (EFO_0003047), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Polycystic Ovary Syndrome (EFO_0000660), Oral Leukoplakia (HP_0002745), Crohn'S Disease (EFO_0000384), Prostate Cancer (MONDO_0008315), Myxoid Liposarcoma (EFO_0000613), Intracerebral Hemorrhage (EFO_0005669), Hypertension (EFO_0000537), Non-Alcoholic Steatohepatitis (EFO_1001249), Cardiovascular Disease (EFO_0000319), Parkinson Disease (MONDO_0005180), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Acute Myeloid Leukemia (EFO_0000222), Chronic Granulomatous Disease (MONDO_0018305), Autism Spectrum Disorder (EFO_0003756), Dedifferentiated Liposarcoma (EFO_0003085), Adrenomyeloneuropathy (MONDO_0015339), Pancreatic Carcinoma (EFO_0002618), Asthma (MONDO_0004979), Anemia (Phenotype) (EFO_0004272), Stroke (EFO_0000712), Abnormal Glucose Tolerance (EFO_0002546), Hypercholesterolemia (HP_0003124), Thyroid Cancer (MONDO_0002108), Inflammation (MP_0001845), Chronic Hepatitis C Virus Infection (EFO_0004220), Rheumatoid Arthritis (EFO_0000685), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Hepatic Steatosis (HP_0001397), Brain Cancer (MONDO_0001657), Pulmonary Alveolar Proteinosis (MONDO_0001437), Chronic Kidney Disease (EFO_0003884), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Amyotrophic Lateral Sclerosis (MONDO_0004976), Lung Cancer (MONDO_0008903), Cognitive Impairment (HP_0100543), Hepatitis (HP_0012115), Non-Small Cell Lung Carcinoma (EFO_0003060), Hiv-Associated Lipodystrophy Syndrome (EFO_1001348), Meningioma (MONDO_0016642), Polycystic Kidney Disease (EFO_0008620), Melanoma (EFO_0000756), Metabolic Syndrome (EFO_0000195), Type 1 Diabetes Mellitus (MONDO_0005147), Major Depressive Disorder (MONDO_0002009), Cystic Fibrosis (MONDO_0009061), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), X-Linked Adrenoleukodystrophy (Orphanet_43)", 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5535', 'drugName': 'Leriglitazone', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydroxypioglitazone, Leriglitazone, MIN-102, Min-102', 'linkedDiseasesDrug_string': 'Adrenoleukodystrophy (MONDO_0018544), Friedreich Ataxia (MONDO_0100339)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.995 | Q17 | What gene does the drug Tak-901 target? | The drug Tak-901 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene AURKB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tak-901%" OR LOWER(tradeNames_string) LIKE "%tak-901%" OR LOWER(drugSynonyms_string) LIKE "%tak-901%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_122', 'drugName': 'Tak-901', 'tradeNames_string': '', 'drugSynonyms_string': 'Tak-901', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Primary Myelofibrosis (EFO_0002430), Chronic Lymphocytic Leukemia (EFO_0000095), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Waldenstrom Macroglobulinemia (EFO_0009441), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1707 | Q17 | What gene does the drug Trifluoperazine Hydrochloride target? | The drug Trifluoperazine Hydrochloride targets 5 genes: DRD4, HTR2A, DRD2, HTR2C and DRD3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trifluoperazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%trifluoperazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%trifluoperazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5532', 'drugName': 'Trifluoperazine Hydrochloride', 'tradeNames_string': 'Stelazine, Trifluoperazine hydrochloride', 'drugSynonyms_string': 'NSC-757369, Trifluoperazine HCl, Trifluoperazine dihydrochloride, Trifluoperazine hcl, Trifluoperazine hydrochloride, Trifluoperazine maleate', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Anxiety Disorder (EFO_0006788), Mental Or Behavioural Disorder (EFO_0000677)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5533', 'drugName': 'Trifluoperazine Hydrochloride', 'tradeNames_string': 'Stelazine, Trifluoperazine hydrochloride', 'drugSynonyms_string': 'NSC-757369, Trifluoperazine HCl, Trifluoperazine dihydrochloride, Trifluoperazine hcl, Trifluoperazine hydrochloride, Trifluoperazine maleate', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Anxiety Disorder (EFO_0006788), Mental Or Behavioural Disorder (EFO_0000677)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5534', 'drugName': 'Trifluoperazine Hydrochloride', 'tradeNames_string': 'Stelazine, Trifluoperazine hydrochloride', 'drugSynonyms_string': 'NSC-757369, Trifluoperazine HCl, Trifluoperazine dihydrochloride, Trifluoperazine hcl, Trifluoperazine hydrochloride, Trifluoperazine maleate', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Anxiety Disorder (EFO_0006788), Mental Or Behavioural Disorder (EFO_0000677)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1285 | Q17 | What gene does the drug Canrenoate Potassium target? | The drug Canrenoate Potassium targets the gene NR3C2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%canrenoate potassium%" OR LOWER(tradeNames_string) LIKE "%canrenoate potassium%" OR LOWER(drugSynonyms_string) LIKE "%canrenoate potassium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_82', 'drugName': 'Canrenoate Potassium', 'tradeNames_string': 'Soldactone, Spiroctan-m', 'drugSynonyms_string': 'Canrenoate potassium, Canrenone free acid potassium salt, Kanrenol, NSC-757789, Potassium canrenoate, SC-14266', 'linkedDiseasesDrug_string': 'St Elevation Myocardial Infarction (EFO_0008585), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1645 | Q17 | What gene does the drug Clonidine Hydrochloride target? | The drug Clonidine Hydrochloride targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clonidine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%clonidine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%clonidine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4092', 'drugName': 'Clonidine Hydrochloride', 'tradeNames_string': 'Catapres, Catapres p.l., Catapres tts 1, Catapres tts 2, Catapres tts 3, Clonidine hydrochloride, Dixarit, Duraclon, Jenloga, Kapvay', 'drugSynonyms_string': 'Clonidine hcl, Clonidine hydrochloride, Dichloranilino imidazolin, NSC-756699, ST-155', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Pain (EFO_0003843), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2038', 'drugName': 'Apraclonidine Hydrochloride', 'tradeNames_string': 'Apraclonidine hydrochloride, Iopidine', 'drugSynonyms_string': 'AL-02145, AL02145, Aplonidine hydrochloride, Apraclonidine hcl, Apraclonidine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.886 | Q17 | What gene does the drug Kw-2450 target? | The drug Kw-2450 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: IGF1R and INSR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kw-2450%" OR LOWER(tradeNames_string) LIKE "%kw-2450%" OR LOWER(drugSynonyms_string) LIKE "%kw-2450%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3066', 'drugName': 'Kw-2450', 'tradeNames_string': '', 'drugSynonyms_string': 'KW-2450, Kw-2450', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3067', 'drugName': 'Kw-2450', 'tradeNames_string': '', 'drugSynonyms_string': 'KW-2450, Kw-2450', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.827 | Q17 | What gene does the drug Fruquintinib target? | The drug Fruquintinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: FLT1, FLT4 and KDR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fruquintinib%" OR LOWER(tradeNames_string) LIKE "%fruquintinib%" OR LOWER(drugSynonyms_string) LIKE "%fruquintinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1715', 'drugName': 'Fruquintinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Fruquintinib, HMPL-013, HMPL013, Hmpl-013', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Rectum Cancer (EFO_1000657), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Colorectal Neoplasm (EFO_0004142), Endometrial Cancer (MONDO_0011962), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Soft Tissue Sarcoma (EFO_1001968), Kidney Disease (EFO_0003086), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Malignant Colon Neoplasm (MONDO_0021063)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1660 | Q17 | What gene does the drug Amantadine Hydrochloride target? | The drug Amantadine Hydrochloride targets 7 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, GRIN3B, GRIN1 and GRIN2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amantadine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%amantadine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%amantadine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_768', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_string': 'Amantadine hydrochloride, Gocovri, Lysovir, Mantadine, Osmolex er, Symadine, Symmetrel', 'drugSynonyms_string': 'Adamantanamine hydrochloride, Amantadine hcl, Amantadine hydrochloride, EXP-105-1, Mantadix, NSC-83653, Osmolex', 'linkedDiseasesDrug_string': 'Parkinsonism (HP_0001300), Secondary Parkinson Disease (EFO_1001175), Infection (EFO_0000544), Mood Disorder (EFO_0004247), Multiple Sclerosis (MONDO_0005301), Covid-19 (MONDO_0100096), Postencephalitic Parkinson Disease (EFO_1001402), Cerebral Atherosclerosis (EFO_1000860), Parkinson Disease (MONDO_0005180), Schizoaffective Disorder (EFO_0005411), Brain Injury (MONDO_0043510), Influenza (EFO_0007328), Schizophrenia (MONDO_0005090), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_769', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_string': 'Amantadine hydrochloride, Gocovri, Lysovir, Mantadine, Osmolex er, Symadine, Symmetrel', 'drugSynonyms_string': 'Adamantanamine hydrochloride, Amantadine hcl, Amantadine hydrochloride, EXP-105-1, Mantadix, NSC-83653, Osmolex', 'linkedDiseasesDrug_string': 'Parkinsonism (HP_0001300), Secondary Parkinson Disease (EFO_1001175), Infection (EFO_0000544), Mood Disorder (EFO_0004247), Multiple Sclerosis (MONDO_0005301), Covid-19 (MONDO_0100096), Postencephalitic Parkinson Disease (EFO_1001402), Cerebral Atherosclerosis (EFO_1000860), Parkinson Disease (MONDO_0005180), Schizoaffective Disorder (EFO_0005411), Brain Injury (MONDO_0043510), Influenza (EFO_0007328), Schizophrenia (MONDO_0005090), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.972 | Q17 | What gene does the drug Gatipotuzumab target? | The drug Gatipotuzumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MUC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gatipotuzumab%" OR LOWER(tradeNames_string) LIKE "%gatipotuzumab%" OR LOWER(drugSynonyms_string) LIKE "%gatipotuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3492', 'drugName': 'Gatipotuzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Gatipotuzumab', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1049 | Q17 | What gene does the drug Edoxaban Tosylate target? | The drug Edoxaban Tosylate targets the gene F10. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%edoxaban tosylate%" OR LOWER(tradeNames_string) LIKE "%edoxaban tosylate%" OR LOWER(drugSynonyms_string) LIKE "%edoxaban tosylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5025', 'drugName': 'Edoxaban Tosylate', 'tradeNames_string': 'Savaysa', 'drugSynonyms_string': 'DU-176B, Edoxaban tosilate, Edoxaban tosylate', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Venous Thromboembolism (EFO_0004286), Thrombotic Disease (MONDO_0000831), Pulmonary Embolism (EFO_0003827), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F10 (ENSG00000126218)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.671 | Q17 | What gene does the drug Angiotensin Ii Acetate target? | The drug Angiotensin Ii Acetate targets the gene AGTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%angiotensin ii acetate%" OR LOWER(tradeNames_string) LIKE "%angiotensin ii acetate%" OR LOWER(drugSynonyms_string) LIKE "%angiotensin ii acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3664', 'drugName': 'Angiotensin Ii Acetate', 'tradeNames_string': 'Giapreza', 'drugSynonyms_string': 'Angiotensin ii acetate, Angiotensin ii acetate human, Angiotensin ii triacetate, Human angiotensin ii acetate salt', 'linkedDiseasesDrug_string': 'Septic Shock (EFO_0006834)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.145 | Q17 | What gene does the drug Sr16234 target? | The drug Sr16234 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sr16234%" OR LOWER(tradeNames_string) LIKE "%sr16234%" OR LOWER(drugSynonyms_string) LIKE "%sr16234%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_534', 'drugName': 'Sr16234', 'tradeNames_string': '', 'drugSynonyms_string': '', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5832', 'drugName': 'Sr16234', 'tradeNames_string': '', 'drugSynonyms_string': 'HLX-801, SR-16234, Sr16234, TAS-108, TS-108', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1518 | Q17 | What gene does the drug Triflupromazine target? | The drug Triflupromazine targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%triflupromazine%" OR LOWER(tradeNames_string) LIKE "%triflupromazine%" OR LOWER(drugSynonyms_string) LIKE "%triflupromazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_203', 'drugName': 'Triflupromazine', 'tradeNames_string': 'Fluopromazine, Nivoman, Vesprin, Vetame', 'drugSynonyms_string': 'Fluopromazine, Triflupromazine', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4009', 'drugName': 'Triflupromazine Hydrochloride', 'tradeNames_string': 'Vesprin', 'drugSynonyms_string': 'MC-4703, NSC-14959, NSC-17473, Triflupromazine hcl, Triflupromazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1999 | Q17 | What gene does the drug Denileukin Diftitox target? | The drug Denileukin Diftitox targets 4 genes: IL2RA, EEF2, IL2RB and IL2RG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%denileukin diftitox%" OR LOWER(tradeNames_string) LIKE "%denileukin diftitox%" OR LOWER(drugSynonyms_string) LIKE "%denileukin diftitox%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5633', 'drugName': 'Denileukin Diftitox', 'tradeNames_string': 'Ontak', 'drugSynonyms_string': 'DAB(SUB 389)IL2, DAB-389IL2, DAB389 IL2, DAB389IL2, Denileukin, Denileukin diftitox, E-7272, E-7777, E7272, E7777, LY-335348, LY335348', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Graft Versus Host Disease (MONDO_0013730), Ovarian Cancer (MONDO_0008170), Fallopian Tube Carcinoma (EFO_1000251), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Peritoneum Cancer (MONDO_0002087), Cutaneous T-Cell Lymphoma (EFO_0002913), Cutaneous Melanoma (EFO_0000389), Endometrioid Carcinoma (EFO_0000466), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Fallopian Tube Cancer (MONDO_0002158), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL2RA (ENSG00000134460), IL2RG (ENSG00000147168), IL2RB (ENSG00000100385), EEF2 (ENSG00000167658)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5634', 'drugName': 'Denileukin Diftitox', 'tradeNames_string': 'Ontak', 'drugSynonyms_string': 'DAB(SUB 389)IL2, DAB-389IL2, DAB389 IL2, DAB389IL2, Denileukin, Denileukin diftitox, E-7272, E-7777, E7272, E7777, LY-335348, LY335348', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Graft Versus Host Disease (MONDO_0013730), Ovarian Cancer (MONDO_0008170), Fallopian Tube Carcinoma (EFO_1000251), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Carcinoma (EFO_0002618), Peritoneum Cancer (MONDO_0002087), Cutaneous T-Cell Lymphoma (EFO_0002913), Cutaneous Melanoma (EFO_0000389), Endometrioid Carcinoma (EFO_0000466), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Fallopian Tube Cancer (MONDO_0002158), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL2RA (ENSG00000134460), IL2RG (ENSG00000147168), IL2RB (ENSG00000100385), EEF2 (ENSG00000167658)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.871 | Q17 | What gene does the drug Saralasin Acetate target? | The drug Saralasin Acetate targets the gene AGTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%saralasin acetate%" OR LOWER(tradeNames_string) LIKE "%saralasin acetate%" OR LOWER(drugSynonyms_string) LIKE "%saralasin acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4566', 'drugName': 'Saralasin Acetate', 'tradeNames_string': 'Sarenin', 'drugSynonyms_string': 'P-113, Saralasin acetate, Saralasin hydrated acetate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.427 | Q17 | What gene does the drug Quinidine Gluconate target? | The drug Quinidine Gluconate targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quinidine gluconate%" OR LOWER(tradeNames_string) LIKE "%quinidine gluconate%" OR LOWER(drugSynonyms_string) LIKE "%quinidine gluconate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2256', 'drugName': 'Quinidine Gluconate', 'tradeNames_string': 'Duraquin, Quinact, Quinaglute, Quinalan, Quinatime, Quinidine gluconate', 'drugSynonyms_string': 'Dura-tab, Gluconic acid quinidine salt, Gluquinate, NSC-757297, Quinidine gluconate, Quinidine mono-d-gluconate, Quinidine monogluconate, d-', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Malaria (EFO_0001068)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.643 | Q17 | What gene does the drug Biperiden target? | The drug Biperiden targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%biperiden%" OR LOWER(tradeNames_string) LIKE "%biperiden%" OR LOWER(drugSynonyms_string) LIKE "%biperiden%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1469', 'drugName': 'Biperiden', 'tradeNames_string': 'Akineton', 'drugSynonyms_string': 'Akineton, Akineton-, Biperiden, Biperidenum, KL 373, NSC-759145', 'linkedDiseasesDrug_string': 'Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Cocaine Dependence (EFO_0002610), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1550', 'drugName': 'Biperiden Hydrochloride', 'tradeNames_string': 'Akineton, Akineton ret', 'drugSynonyms_string': 'Akinophyl, Biperiden hcl, Biperiden hydrochloride, Biperideni hydrochloridum, NSC-170950, NSC-84989, Tasmolin', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6214', 'drugName': 'Biperiden Lactate', 'tradeNames_string': 'Akineton', 'drugSynonyms_string': 'Biperiden lactate', 'linkedDiseasesDrug_string': 'Brain Injury (MONDO_0043510)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1408 | Q17 | What gene does the drug Rg-7376 target? | The drug Rg-7376 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene RAF1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rg-7376%" OR LOWER(tradeNames_string) LIKE "%rg-7376%" OR LOWER(drugSynonyms_string) LIKE "%rg-7376%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4205', 'drugName': 'Rg-7376', 'tradeNames_string': '', 'drugSynonyms_string': 'PLX-5568, Rg-7376', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'RAF1 (ENSG00000132155)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.806 | Q17 | What gene does the drug Procaine target? | The drug Procaine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%procaine%" OR LOWER(tradeNames_string) LIKE "%procaine%" OR LOWER(drugSynonyms_string) LIKE "%procaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1754', 'drugName': 'Benoxinate', 'tradeNames_string': '', 'drugSynonyms_string': 'Benoxinate, Conjucain, Dorsacain, Monofree oxybuprocaine, Oxybucaine, Oxybuprocaine', 'linkedDiseasesDrug_string': 'Pruritus (HP_0000989)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3148', 'drugName': 'Merethoxylline Procaine', 'tradeNames_string': '', 'drugSynonyms_string': 'Merethoxyline procaine, Merethoxylline procaine, Procaine merethoxylline', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2951', 'drugName': 'Procaine Hydrochloride', 'tradeNames_string': 'Novocain, Pasconeural n, Procaine hydrochloride', 'drugSynonyms_string': 'Anestil, Enpro, Jenacaine, Medaject, NSC-757280, Naucaine, Neocaine, Omnicain, Planocaine, Procaine hcl, Procaine hydrochloride, Procaini hydrochloridum, Rocain, SP-01A, SP01A, Sp01a, Syntocain', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3418', 'drugName': 'Procaine', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-169497, Novocain, Procaine', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102), Hemorrhoid (EFO_0009552), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_4967', 'drugName': 'Procainamide Hydrochloride', 'tradeNames_string': 'Biocoryl, Novocainamid, Procainamide hydrochloride, Procan, Procan sr, Procanbid, Procapan, Pronestyl, Pronestyl-sr', 'drugSynonyms_string': 'Amidoprocaine, Cardiorytmin, NSC-757279, Procainamide HCl, Procainamide hcl, Procainamide hydrochloride, Procainamidi hydrochloridum', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2819', 'drugName': 'Benoxinate Hydrochloride', 'tradeNames_string': 'Benoxinate hydrochloride', 'drugSynonyms_string': 'Benoxinate hcl, Benoxinate hydrochloride, NSC-759847, Oxibuprocaine chloride, Oxybuprocaine hcl, Oxybuprocaine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_2193', 'drugName': 'Chloroprocaine Hydrochloride', 'tradeNames_string': 'Ampres, Chloroprocaine hydrochloride, Clorotekal, Nesacaine, Nesacaine-mpf', 'drugSynonyms_string': 'Chloroprocaine HCl, Chloroprocaine hcl, Chloroprocaine hydrochloride, Chlorprocaine chloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_1606', 'drugName': 'Chloroprocaine', 'tradeNames_string': '', 'drugSynonyms_string': '2-chloroprocaine, Chloroprocaine', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Pregnancy (EFO_0002950), Pain (EFO_0003843)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1067 | Q17 | What gene does the drug Daglutril target? | The drug Daglutril is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: MME and ECE1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daglutril%" OR LOWER(tradeNames_string) LIKE "%daglutril%" OR LOWER(drugSynonyms_string) LIKE "%daglutril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1796', 'drugName': 'Daglutril', 'tradeNames_string': '', 'drugSynonyms_string': 'Daglutril, SLV-306, SLV306', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ECE1 (ENSG00000117298), MME (ENSG00000196549)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1797', 'drugName': 'Daglutril', 'tradeNames_string': '', 'drugSynonyms_string': 'Daglutril, SLV-306, SLV306', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ECE1 (ENSG00000117298), MME (ENSG00000196549)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.622 | Q17 | What gene does the drug Meloxicam target? | The drug Meloxicam targets the gene PTGS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%meloxicam%" OR LOWER(tradeNames_string) LIKE "%meloxicam%" OR LOWER(drugSynonyms_string) LIKE "%meloxicam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_988', 'drugName': 'Meloxicam', 'tradeNames_string': 'Anjeso, Meloxicam, Mobic, Qmiiz odt, Vivlodex', 'drugSynonyms_string': 'Acticam, Contacera, Coxicam, Emdocam, Flexicam, Inflacam, Loxicom, Melfax, Melosus, Melovem, Meloxicam, Meloxidolor, Meloxidyl, Meloxivet, Meloxoral, Metacam, Movatec, N-1539, N1539, Recocam, Revitacam, Rheumocam, UH-AC 62XX, UH-AC-62 XX, UHAC-62XX', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Rheumatic Disease (EFO_0005755), Pharyngitis (MONDO_0002258), Osteoarthritis (MONDO_0005178), Juvenile Idiopathic Arthritis (EFO_0002609), Ankylosing Spondylitis (EFO_0003898), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Tuberculosis (MONDO_0018076), Dysmenorrhea (HP_0100607), Systemic Lupus Erythematosus (MONDO_0007915), Shoulder Pain (HP_0030834), Low Back Pain (HP_0003419), Rheumatoid Arthritis (EFO_0000685), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.298 | Q17 | What gene does the drug Emibetuzumab target? | The drug Emibetuzumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MET. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%emibetuzumab%" OR LOWER(tradeNames_string) LIKE "%emibetuzumab%" OR LOWER(drugSynonyms_string) LIKE "%emibetuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4901', 'drugName': 'Emibetuzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'C-8H241, Emibetuzumab, LA480, LY-2875358, LY2875358, La-480', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Small Cell Lung Carcinoma (EFO_0003060), Gastric Cancer (MONDO_0001056)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MET (ENSG00000105976)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.912 | Q17 | What gene does the drug R-333 target? | The drug R-333 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: JAK3 and SYK | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%r-333%" OR LOWER(tradeNames_string) LIKE "%r-333%" OR LOWER(drugSynonyms_string) LIKE "%r-333%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4540', 'drugName': 'Salmeterol Xinafoate', 'tradeNames_string': 'Serevent', 'drugSynonyms_string': 'GR 33343 G, GR-33343 G, GR-33343X, LIPO-202, Salmeterol 1-hydroxy-2-naphthoate, Salmeterol xinafoate', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Obesity (EFO_0001073), Chronic Obstructive Pulmonary Disease (EFO_0000341), Emphysema (EFO_0000464), Bronchiolitis Obliterans (EFO_0007183)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4770', 'drugName': 'Salmeterol', 'tradeNames_string': 'Beglan, Neovent, Serevent, Soltel, Vertine', 'drugSynonyms_string': 'Cryogenine, GR 33343 X, GR-33343-X, GR-33343X, NSC-272693, SN408D, Salmaterol, Salmeterol, Serevent', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Asthma (MONDO_0004979), Bronchospasm (HP_0025428), Obesity (EFO_0001073), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Bronchiolitis Obliterans (EFO_0007183), Emphysema (EFO_0000464), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_854', 'drugName': 'R-333', 'tradeNames_string': '', 'drugSynonyms_string': 'R-333', 'linkedDiseasesDrug_string': 'Systemic Lupus Erythematosus (MONDO_0007915)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), JAK3 (ENSG00000105639)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_855', 'drugName': 'R-333', 'tradeNames_string': '', 'drugSynonyms_string': 'R-333', 'linkedDiseasesDrug_string': 'Systemic Lupus Erythematosus (MONDO_0007915)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), JAK3 (ENSG00000105639)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.917 | Q17 | What gene does the drug Carbamazepine target? | The drug Carbamazepine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carbamazepine%" OR LOWER(tradeNames_string) LIKE "%carbamazepine%" OR LOWER(drugSynonyms_string) LIKE "%carbamazepine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5883', 'drugName': 'Carbamazepine', 'tradeNames_string': 'Arbil mr, Carbagen sr, Carbamazepine, Carbatrol, Carnexiv, Epimaz, Epimaz ret, Epitol, Equetro, Sirtal ret, Tegretol, Tegretol Xr, Tegretol chewtab, Tegretol prolonged release, Tegretol-xr, Teril, Teril ret, Timonil 200 ret, Timonil 400 ret', 'drugSynonyms_string': 'Biston, Carbamazepine, Carbamazepine anhydrous, Carbamazepine extended release, Carbamazepinum, Finlepsin, G-32883, GEIGY 32883, Karbamazepin, Karbelex, NSC-169864, Neurotol, Neurotop, Sirtal, Stazepine, Tegretal, Telesmin, Timonil', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764), Bipolar I Disorder (EFO_0009963), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Seizure (HP_0001250), Hepatitis B Virus Infection (EFO_0004197), Dementia (HP_0000726), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985), Trigeminal Neuralgia (EFO_1001219), Photosensitive Epilepsy (MONDO_0015643)', 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_1913', 'drugName': 'Oxcarbazepine', 'tradeNames_string': 'Oxcarbazepine, Oxtellar xr, Trileptal', 'drugSynonyms_string': 'GP-47680, KIN-493, NSC-758693, Oxcarbamazepine, Oxcarbazepine, SPN-804', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Aggressive Behavior (EFO_0003015), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Seizure (HP_0001250), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1903 | Q17 | What gene does the drug Lisdexamfetamine target? | The drug Lisdexamfetamine targets 3 genes: SLC6A2, SLC6A3 and SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lisdexamfetamine%" OR LOWER(tradeNames_string) LIKE "%lisdexamfetamine%" OR LOWER(drugSynonyms_string) LIKE "%lisdexamfetamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2132', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6178', 'drugName': 'Lisdexamfetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'L-lysine-dextroamphetamine, Lisdexamfetamine, Lisdexamphetamine', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Eating Disorder (EFO_0005203), Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Cocaine Dependence (EFO_0002610), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Major Depressive Disorder (MONDO_0002009), Insomnia (EFO_0004698), Bulimia Nervosa (EFO_0005204), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6177', 'drugName': 'Lisdexamfetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'L-lysine-dextroamphetamine, Lisdexamfetamine, Lisdexamphetamine', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Eating Disorder (EFO_0005203), Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Cocaine Dependence (EFO_0002610), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Major Depressive Disorder (MONDO_0002009), Insomnia (EFO_0004698), Bulimia Nervosa (EFO_0005204), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2130', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2131', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6179', 'drugName': 'Lisdexamfetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'L-lysine-dextroamphetamine, Lisdexamfetamine, Lisdexamphetamine', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Eating Disorder (EFO_0005203), Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Cocaine Dependence (EFO_0002610), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Major Depressive Disorder (MONDO_0002009), Insomnia (EFO_0004698), Bulimia Nervosa (EFO_0005204), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.91 | Q17 | What gene does the drug Imc-Gp100 target? | The drug Imc-Gp100 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: CD3E, CD3G, PMEL and CD3D | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%imc-gp100%" OR LOWER(tradeNames_string) LIKE "%imc-gp100%" OR LOWER(drugSynonyms_string) LIKE "%imc-gp100%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5274', 'drugName': 'Imc-Gp100', 'tradeNames_string': '', 'drugSynonyms_string': 'IMC-GP100', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PMEL (ENSG00000185664), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5275', 'drugName': 'Imc-Gp100', 'tradeNames_string': '', 'drugSynonyms_string': 'IMC-GP100', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PMEL (ENSG00000185664), CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.42 | Q17 | What gene does the drug Medi-8968 target? | The drug Medi-8968 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL1R1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%medi-8968%" OR LOWER(tradeNames_string) LIKE "%medi-8968%" OR LOWER(drugSynonyms_string) LIKE "%medi-8968%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2001', 'drugName': 'Medi-8968', 'tradeNames_string': '', 'drugSynonyms_string': 'MEDI-8968, Medi-8968', 'linkedDiseasesDrug_string': 'Hidradenitis Suppurativa (EFO_1000710), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL1R1 (ENSG00000115594)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1803 | Q17 | What gene does the drug Taplitumomab Paptox target? | The drug Taplitumomab Paptox is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD19. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%taplitumomab paptox%" OR LOWER(tradeNames_string) LIKE "%taplitumomab paptox%" OR LOWER(drugSynonyms_string) LIKE "%taplitumomab paptox%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4360', 'drugName': 'Taplitumomab Paptox', 'tradeNames_string': '', 'drugSynonyms_string': 'Taplitumomab paptox', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD19 (ENSG00000177455)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1934 | Q17 | What gene does the drug Olanzapine Pamoate target? | The drug Olanzapine Pamoate targets 5 genes: DRD4, HTR2A, DRD2, HTR2C and DRD3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olanzapine pamoate%" OR LOWER(tradeNames_string) LIKE "%olanzapine pamoate%" OR LOWER(drugSynonyms_string) LIKE "%olanzapine pamoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1529', 'drugName': 'Olanzapine Pamoate', 'tradeNames_string': 'Zyprexa relprevv', 'drugSynonyms_string': 'Olanzapine (as embonate), Olanzapine embonate, Olanzapine pamoate, Olanzapine pamoate anhydrous, Olanzapine pamoate monohydrate, Zypadhera', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Agitation (HP_0000713), Bipolar I Disorder (EFO_0009963)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_1530', 'drugName': 'Olanzapine Pamoate', 'tradeNames_string': 'Zyprexa relprevv', 'drugSynonyms_string': 'Olanzapine (as embonate), Olanzapine embonate, Olanzapine pamoate, Olanzapine pamoate anhydrous, Olanzapine pamoate monohydrate, Zypadhera', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Agitation (HP_0000713), Bipolar I Disorder (EFO_0009963)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_1531', 'drugName': 'Olanzapine Pamoate', 'tradeNames_string': 'Zyprexa relprevv', 'drugSynonyms_string': 'Olanzapine (as embonate), Olanzapine embonate, Olanzapine pamoate, Olanzapine pamoate anhydrous, Olanzapine pamoate monohydrate, Zypadhera', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Agitation (HP_0000713), Bipolar I Disorder (EFO_0009963)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.134 | Q17 | What gene does the drug Progesterone target? | The drug Progesterone targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%progesterone%" OR LOWER(tradeNames_string) LIKE "%progesterone%" OR LOWER(drugSynonyms_string) LIKE "%progesterone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_184', 'drugName': 'Desoxycorticosterone Acetate', 'tradeNames_string': 'Doca, Percorten', 'drugSynonyms_string': '11-deoxycorticosterone, 11-deoxycorticosterone acetate, 21-hydroxyprogesterone, Deoxycorticosterone, Deoxycorticosterone acetate, Deoxycortone, Desoxycorticosterone, Desoxycorticosterone acetate, Desoxycortone, Desoxycortone acetate, NSC-11319, NSC-9567', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2722', 'drugName': 'Medroxyprogesterone Acetate', 'tradeNames_string': 'Adgyn medro, Amen, Climanor, Curretab, Cycrin, Depo-progevera, Depo-provera, Depo-provera oncology, Depo-subq provera 104, Farlutal, Farlutal 100, Farlutal 200, Farlutal 250, Farlutal 500, Lunelle, Medroxyprogesterone acetate, Provera, Sayana press', 'drugSynonyms_string': 'Amen, Depot-medroxyprogesterone acetate, Farlutal inyectable, G03AC06, Medroxiprogesterone acetate, Medroxyprogesterone, Medroxyprogesterone 17-acetate, Medroxyprogesterone Acetate, Medroxyprogesterone acetate, Medroxyprogesteroni acetas, NSC-21171, NSC-26386, NSC-27408, Prempro, Provera, TV-46046', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Coronary Artery Disease (EFO_0001645), Hemorrhage (MP_0001914), Pain (EFO_0003843), Systemic Lupus Erythematosus (MONDO_0007915), Myelodysplastic Syndrome (EFO_0000198), Endometrial Cancer (MONDO_0011962), Pregnancy (EFO_0002950), Hot Flashes (HP_0031217), Prostate Adenocarcinoma (EFO_0000673), Myocardial Ischemia (EFO_1001375), Osteoporosis (EFO_0003882), Hypertension (EFO_0000537), Premature Ovarian Insufficiency (HP_0008209), Renal Carcinoma (EFO_0002890), Thrombotic Disease (MONDO_0000831), Endometriosis (EFO_0001065), Turner Syndrome (MONDO_0019499), Menopause (EFO_0003922), Infertility (EFO_0000545), Hypercholesterolemia (HP_0003124), Renal Cell Carcinoma (EFO_0000681), Hiv-1 Infection (EFO_0000180), Endometrial Neoplasm (EFO_0004230), Hyperplasia (EFO_0000536), Menorrhagia (HP_0000132), Sleep Apnea (EFO_0003877), Hiv Infection (EFO_0000764), Heart Disease (EFO_0003777), Neoplasm (EFO_0000616), Kidney Cancer (MONDO_0002367)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4832', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_string': 'Delalutin, Hydroxyprogesterone caproate, Makena, Makena (autoinjector), Makena preservative free, Proluton depot', 'drugSynonyms_string': '17-ohpc, 17.alpha.-caproyloxy-p4, Depo-proluton, Hormofort, Hydroxyprogesterone, Hydroxyprogesterone caproate, Hydroxyprogesterone hexanoate, Hylutin, NSC-17592, Oxiprogesterone caproate, Pharlon, Primolut depot, Procyte depo, Proge, Syngynon, Teralutil', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Premature Birth (EFO_0003917)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2024', 'drugName': 'Brexanolone', 'tradeNames_string': 'Zulresso', 'drugSynonyms_string': 'Allopregnan-3.alpha.-ol-20-one, Allopregnanolone, Allotetrahydroprogesterone, Brexanolone, SAGE-547, SGE-102', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Alzheimer Disease (MONDO_0004975), Postpartum Depression (EFO_0007453), Essential Tremor (EFO_0003108), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Status Epilepticus (EFO_0008526), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_4799', 'drugName': 'Progesterone', 'tradeNames_string': 'Crinone, Cyclogest, Endometrin, Gesterol, Lutigest, Milprosa, Prochieve, Progesta-care, Progestasert, Progesterone, Progestin, Prometrium, Regumate, Serenity for women, Syngestrone, Utrogestan', 'drugSynonyms_string': 'NSC-64377, NSC-9704, Progesterone, Progesterone, micronized, Progesteronum, U 3672', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Coronary Artery Disease (EFO_0001645), Hemorrhage (MP_0001914), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Cannabis Dependence (EFO_0007191), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Placenta Praevia (EFO_0007442), Endometrial Cancer (MONDO_0011962), Pregnancy (EFO_0002950), Anorexia Nervosa (MONDO_0005351), Myocardial Ischemia (EFO_1001375), Breast Neoplasm (EFO_0003869), Osteopenia (HP_0000938), Polycystic Ovary Syndrome (EFO_0000660), Gliosarcoma (EFO_1001465), Postpartum Depression (EFO_0007453), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Vulvar Lichen Sclerosus (EFO_1000623), Nicotine Dependence (EFO_0003768), Osteoporosis (EFO_0003882), Hypertension (EFO_0000537), Thrombotic Disease (MONDO_0000831), Intermediate Coronary Syndrome (EFO_1000985), Amenorrhea (EFO_0010269), Epilepsy (EFO_0000474), Cocaine Dependence (EFO_0002610), Methamphetamine Dependence (EFO_0004701), Memory Impairment (EFO_0001072), Cervical Intraepithelial Neoplasia (MONDO_0022394), Premature Birth (EFO_0003917), Menopause (EFO_0003922), Orthostatic Intolerance (EFO_1000645), Infertility (EFO_0000545), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Brain Injury (MONDO_0043510), Ovarian Neoplasm (EFO_0003893), Female Infertility (EFO_0008560), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1566 | Q17 | What gene does the drug Secobarbital Sodium target? | The drug Secobarbital Sodium targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%secobarbital sodium%" OR LOWER(tradeNames_string) LIKE "%secobarbital sodium%" OR LOWER(drugSynonyms_string) LIKE "%secobarbital sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5547', 'drugName': 'Secobarbital', 'tradeNames_string': 'Seconal', 'drugSynonyms_string': '(rs)-secobarbital, Evronal, Hypotrol, Immenox, Meballymal, Quinalbarbital, Secobarbital, Secobarbital cii, Secobarbital sodium free acid, Secobarbitone, Somatarax', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_6371', 'drugName': 'Secobarbital Sodium', 'tradeNames_string': 'Secobarbital sodium, Seconal sodium, Seconesin, Tuinal', 'drugSynonyms_string': '(rs)-secobarbital sodium, Barbosec, Evronal sodium, Immenoctal, NSC-10818, Pramil, Quinalbarbitone sodium, Sebar, Secobarbital sodium, Synate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.977 | Q17 | What gene does the drug Amlexanox target? | The drug Amlexanox targets 4 genes: PDE4A, PDE4D, PDE4B and PDE4C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amlexanox%" OR LOWER(tradeNames_string) LIKE "%amlexanox%" OR LOWER(drugSynonyms_string) LIKE "%amlexanox%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4564', 'drugName': 'Amlexanox', 'tradeNames_string': 'Amlexanox, Aphthasol', 'drugSynonyms_string': 'AA-673, Amlexanox, Amoxanox, Aphtheal, CHX 3673, CHX-3673, Elics, Solfa', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536), Oral Mucositis (EFO_1001904)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1070 | Q17 | What gene does the drug Dihydroergotamine Mesylate target? | The drug Dihydroergotamine Mesylate targets the gene HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dihydroergotamine mesylate%" OR LOWER(tradeNames_string) LIKE "%dihydroergotamine mesylate%" OR LOWER(drugSynonyms_string) LIKE "%dihydroergotamine mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5316', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_string': 'D.h.e. 45, Diergo, Dihydergot, Dihydroergotamine mesylate, Tonopan, Trudhesa', 'drugSynonyms_string': 'DHE-45, Dihydroergotamine Methanesulfonate, Dihydroergotamine mesilate, Dihydroergotamine mesylate, Dihydroergotamine methanesulfonate, Migranal, NSC-759848', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1856 | Q17 | What gene does the drug Sotalol Hydrochloride target? | The drug Sotalol Hydrochloride targets 3 genes: KCNH2, ADRB2 and ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sotalol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%sotalol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%sotalol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4569', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugSynonyms_string': 'DL-MJ-1999, Darob, MJ 1999, MJ-1999, NSC-337251, NSC-760358, Sotalol hcl, Sotalol hydrochloride', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4570', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugSynonyms_string': 'DL-MJ-1999, Darob, MJ 1999, MJ-1999, NSC-337251, NSC-760358, Sotalol hcl, Sotalol hydrochloride', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4571', 'drugName': 'Sotalol Hydrochloride', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugSynonyms_string': 'DL-MJ-1999, Darob, MJ 1999, MJ-1999, NSC-337251, NSC-760358, Sotalol hcl, Sotalol hydrochloride', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1346 | Q17 | What gene does the drug Lemborexant target? | The drug Lemborexant targets 2 genes: HCRTR2 and HCRTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lemborexant%" OR LOWER(tradeNames_string) LIKE "%lemborexant%" OR LOWER(drugSynonyms_string) LIKE "%lemborexant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1217', 'drugName': 'Lemborexant', 'tradeNames_string': 'Dayvigo', 'drugSynonyms_string': 'E-2006, E2006, Lemborexant', 'linkedDiseasesDrug_string': 'Sleep Disorder (EFO_0008568), Circadian Rhythm Sleep Disorder (MONDO_0024361), Liver Disease (EFO_0001421), Kidney Disease (EFO_0003086), Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HCRTR2 (ENSG00000137252), HCRTR1 (ENSG00000121764)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1218', 'drugName': 'Lemborexant', 'tradeNames_string': 'Dayvigo', 'drugSynonyms_string': 'E-2006, E2006, Lemborexant', 'linkedDiseasesDrug_string': 'Sleep Disorder (EFO_0008568), Circadian Rhythm Sleep Disorder (MONDO_0024361), Liver Disease (EFO_0001421), Kidney Disease (EFO_0003086), Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HCRTR2 (ENSG00000137252), HCRTR1 (ENSG00000121764)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1831 | Q17 | What gene does the drug Omeprazole Magnesium target? | The drug Omeprazole Magnesium targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%omeprazole magnesium%" OR LOWER(tradeNames_string) LIKE "%omeprazole magnesium%" OR LOWER(drugSynonyms_string) LIKE "%omeprazole magnesium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4440', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_string': 'Esomeprazole magnesium, Nexium, Nexium 24hr', 'drugSynonyms_string': 'Esomeprazole (as magnesium), Esomeprazole magnesium, Esomeprazole magnesium hydrate, Esomeprazole magnesium trihydrate, H199/18 MAGNESIUM TRIHYDRATE', 'linkedDiseasesDrug_string': 'Esophagitis (HP_0100633), Osteoarthritis (MONDO_0005178), Ankylosing Spondylitis (EFO_0003898), Type 2 Diabetes Mellitus (MONDO_0005148), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Rheumatoid Arthritis (EFO_0000685), Chronic Pancreatitis (EFO_0000342), Zollinger-Ellison Syndrome (EFO_0007549), Helicobacter Pylori Infectious Disease (EFO_1000961), Gastroesophageal Reflux Disease (EFO_0003948), Peptic Ulcer Disease (MONDO_0004247)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3369', 'drugName': 'Omeprazole Magnesium', 'tradeNames_string': 'Omeprazole magnesium, Prilosec, Prilosec otc', 'drugSynonyms_string': 'H 168/68 MAGNESIUM, Omeprazole (as magnesium), Omeprazole magnesium, Omeprazole magnesium salt', 'linkedDiseasesDrug_string': 'Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.167 | Q17 | What gene does the drug Balstilimab target? | The drug Balstilimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PDCD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%balstilimab%" OR LOWER(tradeNames_string) LIKE "%balstilimab%" OR LOWER(drugSynonyms_string) LIKE "%balstilimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3787', 'drugName': 'Balstilimab', 'tradeNames_string': '', 'drugSynonyms_string': 'AGEN-2034, AGEN2034, Agen2034, Balstilimab', 'linkedDiseasesDrug_string': 'Diffuse Intrinsic Pontine Glioma (EFO_1000026), Oropharynx Cancer (EFO_1001931), Neoplasm (EFO_0000616), Human Papilloma Virus Infection (EFO_0001668), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Melanoma (EFO_0000756), Endometrial Cancer (MONDO_0011962), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Cervical Cancer (MONDO_0002974), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDCD1 (ENSG00000188389)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.731 | Q17 | What gene does the drug Phenoxybenzamine target? | The drug Phenoxybenzamine targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenoxybenzamine%" OR LOWER(tradeNames_string) LIKE "%phenoxybenzamine%" OR LOWER(drugSynonyms_string) LIKE "%phenoxybenzamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5463', 'drugName': 'Phenoxybenzamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Bensylyt, Benzylyt, Dibenylin, Phenoxybenzamine', 'linkedDiseasesDrug_string': 'Adrenal Gland Pheochromocytoma (EFO_0000239), Cardiovascular Disease (EFO_0000319), Congenital Heart Disease (EFO_0005207)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_1879', 'drugName': 'Phenoxybenzamine Hydrochloride', 'tradeNames_string': 'Dibenyline, Dibenzyline, Phenoxybenzamine hydrochloride', 'drugSynonyms_string': 'Bensylyte hydrochloride, Dibenzylin, Dibenzyline chloride, Dibenzyline hydrochloride, Dibenzyran, NSC-37448, Phenoxybenzamine chloride, Phenoxybenzamine hcl, Phenoxybenzamine hydrochloride', 'linkedDiseasesDrug_string': 'Adrenal Gland Pheochromocytoma (EFO_0000239)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.294 | Q17 | What gene does the drug Volixibat target? | The drug Volixibat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SLC10A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%volixibat%" OR LOWER(tradeNames_string) LIKE "%volixibat%" OR LOWER(drugSynonyms_string) LIKE "%volixibat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6260', 'drugName': 'Volixibat', 'tradeNames_string': '', 'drugSynonyms_string': 'SAR-548304 FREE ACID, Volixibat', 'linkedDiseasesDrug_string': 'Sclerosing Cholangitis (EFO_0004268), Primary Biliary Cirrhosis (EFO_1001486), Intrahepatic Cholestasis (MONDO_0019072)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC10A2 (ENSG00000125255)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1142 | Q17 | What gene does the drug Relatlimab target? | The drug Relatlimab targets the gene LAG3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%relatlimab%" OR LOWER(tradeNames_string) LIKE "%relatlimab%" OR LOWER(drugSynonyms_string) LIKE "%relatlimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2446', 'drugName': 'Relatlimab', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS-986016, Relatlimab, Relatlimab rmbw, Relatlimab-rmbw', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Basal Cell Carcinoma (EFO_0004193), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LAG3 (ENSG00000089692)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1536 | Q17 | What gene does the drug Axitinib target? | The drug Axitinib targets 3 genes: FLT1, FLT4 and KDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%axitinib%" OR LOWER(tradeNames_string) LIKE "%axitinib%" OR LOWER(drugSynonyms_string) LIKE "%axitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4943', 'drugName': 'Axitinib', 'tradeNames_string': 'Inlyta', 'drugSynonyms_string': 'AG-013736, AG-13736, Axitinib, NSC-757441', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Gastric Cancer (MONDO_0001056), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Renal Carcinoma (EFO_0002890), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Endometriosis (EFO_0001065), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Metastasis (EFO_0009708), Thyroid Neoplasm (EFO_0003841), Solitary Fibrous Tumor (MONDO_0016238), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Kidney Neoplasm (EFO_0003865), Skin Neoplasm (EFO_0004198), Carcinoma (EFO_0000313), Biliary Tract Neoplasm (EFO_0003891), Neoplasm (EFO_0000616), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Malignant Pleural Mesothelioma (EFO_0000770), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Pancreatic Neoplasm (EFO_0003860)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1897 | Q17 | What gene does the drug Secretin Synthetic Porcine target? | The drug Secretin Synthetic Porcine targets the gene SCTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%secretin synthetic porcine%" OR LOWER(tradeNames_string) LIKE "%secretin synthetic porcine%" OR LOWER(drugSynonyms_string) LIKE "%secretin synthetic porcine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_462', 'drugName': 'Secretin Synthetic Porcine', 'tradeNames_string': 'Secreflo', 'drugSynonyms_string': 'Porcine secretin acetate salt, RG-1068, Secretin (swine), acetate (salt), Secretin porcine pentaacetate, Secretin synthetic porcine', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCTR (ENSG00000080293)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1006 | Q17 | What gene does the drug Carvedilol target? | The drug Carvedilol targets 6 genes: ADRB2, ADRB1, ADRA1A, ADRA1D, ADRA1B and ADRB3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carvedilol%" OR LOWER(tradeNames_string) LIKE "%carvedilol%" OR LOWER(drugSynonyms_string) LIKE "%carvedilol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3794', 'drugName': 'Carvedilol', 'tradeNames_string': 'Carvedilol, Coreg, Coreg CR, Eucardic 12.5, Eucardic 25, Eucardic 3.125, Eucardic 6.25', 'drugSynonyms_string': 'BM 14.190, BM-14-190, BM-14.190, BM-14190, C07AG02, Carvedilol, Coronis, DQ-2466, Dilatrend, Dimitone, Eucardic, Korvasan, Kredex, NSC-758694, SKF-105517, Talliton', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Coronary Artery Disease (EFO_0001645), Pulmonary Hypertension (MONDO_0005149), Pulmonary Arterial Hypertension (EFO_0001361), Essential Hypertension (MONDO_0001134), Hypoglycemia (HP_0001943), Atrial Fibrillation (EFO_0000275), Post-Traumatic Stress Disorder (EFO_0001358), Congestive Heart Failure (EFO_0000373), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Left Ventricular Hypertrophy (EFO_0003896), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Portal Hypertension (EFO_0000666), Esophageal Varices (EFO_0009545), Lymphoid Leukemia (EFO_0004289), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Vascular Disease (EFO_0004264), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_3793', 'drugName': 'Carvedilol', 'tradeNames_string': 'Carvedilol, Coreg, Coreg CR, Eucardic 12.5, Eucardic 25, Eucardic 3.125, Eucardic 6.25', 'drugSynonyms_string': 'BM 14.190, BM-14-190, BM-14.190, BM-14190, C07AG02, Carvedilol, Coronis, DQ-2466, Dilatrend, Dimitone, Eucardic, Korvasan, Kredex, NSC-758694, SKF-105517, Talliton', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Coronary Artery Disease (EFO_0001645), Pulmonary Hypertension (MONDO_0005149), Pulmonary Arterial Hypertension (EFO_0001361), Essential Hypertension (MONDO_0001134), Hypoglycemia (HP_0001943), Atrial Fibrillation (EFO_0000275), Post-Traumatic Stress Disorder (EFO_0001358), Congestive Heart Failure (EFO_0000373), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Left Ventricular Hypertrophy (EFO_0003896), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Portal Hypertension (EFO_0000666), Esophageal Varices (EFO_0009545), Lymphoid Leukemia (EFO_0004289), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Vascular Disease (EFO_0004264), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_907', 'drugName': 'Carvedilol Phosphate', 'tradeNames_string': 'Coreg cr', 'drugSynonyms_string': 'Carvedilol phosphate, Carvedilol phosphate hemihydrate, Carvedilol phosphate hydrate, SK&F-105517-D, SKF 105517D, SKF-105517D', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_906', 'drugName': 'Carvedilol Phosphate', 'tradeNames_string': 'Coreg cr', 'drugSynonyms_string': 'Carvedilol phosphate, Carvedilol phosphate hemihydrate, Carvedilol phosphate hydrate, SK&F-105517-D, SKF 105517D, SKF-105517D', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1421 | Q17 | What gene does the drug Efgartigimod Alfa target? | The drug Efgartigimod Alfa targets the gene FCGRT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%efgartigimod alfa%" OR LOWER(tradeNames_string) LIKE "%efgartigimod alfa%" OR LOWER(drugSynonyms_string) LIKE "%efgartigimod alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4154', 'drugName': 'Efgartigimod Alfa', 'tradeNames_string': 'Vyvgart', 'drugSynonyms_string': 'ARGX-113, Argx-113, Efgartigimod, Efgartigimod alfa, Efgartigimod alfa fcab, Efgartigimod alfa-fcab, Vyvgart', 'linkedDiseasesDrug_string': 'Autoimmune Thrombocytopenic Purpura (EFO_0007160), Chronic Inflammatory Demyelinating Polyneuropathy (EFO_0009538), Myasthenia Gravis (EFO_0004991), Bullous Pemphigoid (EFO_0007187)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FCGRT (ENSG00000104870)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.785 | Q17 | What gene does the drug Nortriptyline target? | The drug Nortriptyline targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nortriptyline%" OR LOWER(tradeNames_string) LIKE "%nortriptyline%" OR LOWER(drugSynonyms_string) LIKE "%nortriptyline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_598', 'drugName': 'Nortriptyline', 'tradeNames_string': 'Allegron, Aventyl, Motipress, Motival', 'drugSynonyms_string': 'Desitriptilina, Lumbeck, NCI-169453, NSC-757234, Noramitriptyline, Nortrilen, Nortriptyline, Pamelor, Sesaval', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Temporomandibular Joint Disorder (EFO_0005279), Unipolar Depression (EFO_0003761), Nicotine Dependence (EFO_0003768), Small Cell Carcinoma (EFO_0008524), Atopic Eczema (EFO_0000274), Dementia (HP_0000726), Dyspepsia (EFO_0008533), Anxiety (EFO_0005230), Irritable Bowel Syndrome (EFO_0000555), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090), Depressive Disorder (MONDO_0002050), Gastroparesis (EFO_1000948), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_597', 'drugName': 'Nortriptyline', 'tradeNames_string': 'Allegron, Aventyl, Motipress, Motival', 'drugSynonyms_string': 'Desitriptilina, Lumbeck, NCI-169453, NSC-757234, Noramitriptyline, Nortrilen, Nortriptyline, Pamelor, Sesaval', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Temporomandibular Joint Disorder (EFO_0005279), Unipolar Depression (EFO_0003761), Nicotine Dependence (EFO_0003768), Small Cell Carcinoma (EFO_0008524), Atopic Eczema (EFO_0000274), Dementia (HP_0000726), Dyspepsia (EFO_0008533), Anxiety (EFO_0005230), Irritable Bowel Syndrome (EFO_0000555), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090), Depressive Disorder (MONDO_0002050), Gastroparesis (EFO_1000948), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5992', 'drugName': 'Nortriptyline Hydrochloride', 'tradeNames_string': 'Aventyl, Aventyl hydrochloride, Nortriptyline hydrochloride, Pamelor, Psychostyl', 'drugSynonyms_string': '38489, NSC-169453, Nortriptyline hcl, Nortriptyline hydrochloride', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Unipolar Depression (EFO_0003761), Small Cell Carcinoma (EFO_0008524), Atopic Eczema (EFO_0000274), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5991', 'drugName': 'Nortriptyline Hydrochloride', 'tradeNames_string': 'Aventyl, Aventyl hydrochloride, Nortriptyline hydrochloride, Pamelor, Psychostyl', 'drugSynonyms_string': '38489, NSC-169453, Nortriptyline hcl, Nortriptyline hydrochloride', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Unipolar Depression (EFO_0003761), Small Cell Carcinoma (EFO_0008524), Atopic Eczema (EFO_0000274), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.846 | Q17 | What gene does the drug Suxamethonium target? | The drug Suxamethonium targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%suxamethonium%" OR LOWER(tradeNames_string) LIKE "%suxamethonium%" OR LOWER(drugSynonyms_string) LIKE "%suxamethonium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6206', 'drugName': 'Suxamethonium', 'tradeNames_string': '', 'drugSynonyms_string': 'Anectine, Quelicin, Succinylcholine, Succinylcholine cation, Succinylcholine ion, Sucostrin, Suxamethonium, Suxamethonium cation, Suxamethonium ion', 'linkedDiseasesDrug_string': 'Bradycardia (HP_0001662), Stroke (EFO_0000712), Myalgia (HP_0003326)', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2723', 'drugName': 'Succinylcholine Chloride', 'tradeNames_string': 'Anectine, Quelicin, Quelicin preservative free, Scoline, Succinylcholine chloride, Sucostrin, Suxamethonium Chloride', 'drugSynonyms_string': 'Choline chloride succinate (2:1), NSC-49132, Succinylcholine chloride, Suxamethone, Suxamethonii chloridum, Suxamethonium chloride, Suxamethonium chloride dihydrate, Suxamethonium chloride hydrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.352 | Q17 | What gene does the drug Asenapine target? | The drug Asenapine targets 2 genes: HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%asenapine%" OR LOWER(tradeNames_string) LIKE "%asenapine%" OR LOWER(drugSynonyms_string) LIKE "%asenapine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4104', 'drugName': 'Asenapine Maleate', 'tradeNames_string': 'Saphris', 'drugSynonyms_string': 'Asenapine (as maleate), Asenapine maleate, ORG 5222, ORG-5222', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Bipolar Disorder (MONDO_0004985), Stuttering (HP_0025268), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4103', 'drugName': 'Asenapine Maleate', 'tradeNames_string': 'Saphris', 'drugSynonyms_string': 'Asenapine (as maleate), Asenapine maleate, ORG 5222, ORG-5222', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Bipolar Disorder (MONDO_0004985), Stuttering (HP_0025268), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1061', 'drugName': 'Asenapine', 'tradeNames_string': 'Secuado, Sycrest', 'drugSynonyms_string': 'Asenapine', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Bipolar Disorder (MONDO_0004985), Stuttering (HP_0025268), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1060', 'drugName': 'Asenapine', 'tradeNames_string': 'Secuado, Sycrest', 'drugSynonyms_string': 'Asenapine', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Bipolar Disorder (MONDO_0004985), Stuttering (HP_0025268), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1945 | Q17 | What gene does the drug Insulin Susp Protamine Zinc Beef/Pork target? | The drug Insulin Susp Protamine Zinc Beef/Pork targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin susp protamine zinc beef/pork%" OR LOWER(tradeNames_string) LIKE "%insulin susp protamine zinc beef/pork%" OR LOWER(drugSynonyms_string) LIKE "%insulin susp protamine zinc beef/pork%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2164', 'drugName': 'Insulin Susp Protamine Zinc Beef/Pork', 'tradeNames_string': 'Protamine zinc & iletin i (beef-pork)', 'drugSynonyms_string': 'Insulin susp protamine zinc beef/pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.577 | Q17 | What gene does the drug Asciminib target? | The drug Asciminib targets 2 genes: BCR and ABL1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%asciminib%" OR LOWER(tradeNames_string) LIKE "%asciminib%" OR LOWER(drugSynonyms_string) LIKE "%asciminib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3412', 'drugName': 'Asciminib', 'tradeNames_string': '', 'drugSynonyms_string': 'ABL-001, ABL001, ABL001-NX, Abl-001, Asciminib, NVP-ABL001', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Acute Lymphoblastic Leukemia (EFO_0000220), Kidney Disease (EFO_0003086), Biliary Tract Cancer (MONDO_0003060), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3413', 'drugName': 'Asciminib', 'tradeNames_string': '', 'drugSynonyms_string': 'ABL-001, ABL001, ABL001-NX, Abl-001, Asciminib, NVP-ABL001', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Acute Lymphoblastic Leukemia (EFO_0000220), Kidney Disease (EFO_0003086), Biliary Tract Cancer (MONDO_0003060), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4114', 'drugName': 'Asciminib Hydrochloride', 'tradeNames_string': 'Scemblix', 'drugSynonyms_string': 'ABL001-AAA, Asciminib hydrochloride, Scemblix', 'linkedDiseasesDrug_string': 'Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1923 | Q17 | What gene does the drug Dp001 target? | The drug Dp001 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene VDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dp001%" OR LOWER(tradeNames_string) LIKE "%dp001%" OR LOWER(drugSynonyms_string) LIKE "%dp001%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6173', 'drugName': 'Dp001', 'tradeNames_string': '', 'drugSynonyms_string': '2MD, Dp001', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Postmenopausal Osteoporosis (EFO_0003854), Secondary Hyperparathyroidism (EFO_1001173)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1888 | Q17 | What gene does the drug Cnv2197944 target? | The drug Cnv2197944 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CACNA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cnv2197944%" OR LOWER(tradeNames_string) LIKE "%cnv2197944%" OR LOWER(drugSynonyms_string) LIKE "%cnv2197944%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3408', 'drugName': 'Cnv2197944', 'tradeNames_string': '', 'drugSynonyms_string': 'CNV2197944, Cnv-2197944, Cnv2197944', 'linkedDiseasesDrug_string': 'Diabetic Neuropathy (EFO_1000783), Postherpetic Neuralgia (MONDO_0041052)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1470 | Q17 | What gene does the drug Interferon Beta-1B target? | The drug Interferon Beta-1B targets 2 genes: IFNAR1 and IFNAR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%interferon beta-1b%" OR LOWER(tradeNames_string) LIKE "%interferon beta-1b%" OR LOWER(drugSynonyms_string) LIKE "%interferon beta-1b%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5120', 'drugName': 'Interferon Beta-1B', 'tradeNames_string': 'Betaseron, Extavia', 'drugSynonyms_string': 'BAY 86-5046, BAY-86-5046, Interferon beta-1b', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Multiple Sclerosis (MONDO_0005301), Covid-19 (MONDO_0100096), Middle East Respiratory Syndrome (MONDO_0100116), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Cardiomyopathy (EFO_0000318)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1818 | Q17 | What gene does the drug Clometacin target? | The drug Clometacin targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clometacin%" OR LOWER(tradeNames_string) LIKE "%clometacin%" OR LOWER(drugSynonyms_string) LIKE "%clometacin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5380', 'drugName': 'Clometacin', 'tradeNames_string': '', 'drugSynonyms_string': 'C 1656, C-1656, Clometacin, Mindolic acid, R 3959, R-3959', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1317 | Q17 | What gene does the drug Dextrothyroxine Sodium target? | The drug Dextrothyroxine Sodium targets 2 genes: THRA and THRB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dextrothyroxine sodium%" OR LOWER(tradeNames_string) LIKE "%dextrothyroxine sodium%" OR LOWER(drugSynonyms_string) LIKE "%dextrothyroxine sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4368', 'drugName': 'Dextrothyroxine Sodium', 'tradeNames_string': 'Choloxin', 'drugSynonyms_string': 'Anhydrous dextrothyroxine sodium, D-thyroxine sodium salt, Dextrothyroxine sodium, Dextrothyroxine sodium anhydrous, Dextrothyroxine sodium hydrate, Monosodium d-thyroxine hydrate, Sodium dextrothyroxine', 'linkedDiseasesDrug_string': 'Myocardial Infarction (EFO_0000612), Myocardial Ischemia (EFO_1001375)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1501 | Q17 | What gene does the drug At-7519 target? | The drug At-7519 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 20 genes: CDK9, CDK19, CDK3, CDK20, CDK16, CDK18, CDK5, CDK13, CDK12, CDK15, CDK14, CDK10, CDK11B, CDK8, CDK4, CDK2, CDK1, CDK7, CDK17 and CDK6 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%at-7519%" OR LOWER(tradeNames_string) LIKE "%at-7519%" OR LOWER(drugSynonyms_string) LIKE "%at-7519%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2272', 'drugName': 'At-7519', 'tradeNames_string': '', 'drugSynonyms_string': 'AT 7519, AT-7519, AT7519, At-7519, Cdki at7519', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm (EFO_0000616), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK1 (ENSG00000170312), CDK4 (ENSG00000135446), CDK2 (ENSG00000123374), CDK5 (ENSG00000164885), CDK6 (ENSG00000105810), CDK7 (ENSG00000134058), CDK3 (ENSG00000250506), CDK16 (ENSG00000102225), CDK18 (ENSG00000117266), CDK8 (ENSG00000132964), CDK17 (ENSG00000059758), CDK11B (ENSG00000248333), CDK15 (ENSG00000138395), CDK19 (ENSG00000155111), CDK14 (ENSG00000058091), CDK9 (ENSG00000136807), CDK10 (ENSG00000185324), CDK13 (ENSG00000065883), CDK20 (ENSG00000156345), CDK12 (ENSG00000167258)', 'numberLinkedTargets': 20}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.464 | Q17 | What gene does the drug Lornoxicam target? | The drug Lornoxicam targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lornoxicam%" OR LOWER(tradeNames_string) LIKE "%lornoxicam%" OR LOWER(drugSynonyms_string) LIKE "%lornoxicam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5752', 'drugName': 'Lornoxicam', 'tradeNames_string': 'Xefo', 'drugSynonyms_string': 'CTX, Lorcam, Lornoxicam, NSC-759620, RO 13-9297, RO-13-9297, RO-139297', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Alzheimer Disease (MONDO_0004975), Rheumatic Disease (EFO_0005755), Pain (EFO_0003843)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.381 | Q17 | What gene does the drug Almotriptan Malate target? | The drug Almotriptan Malate targets 3 genes: HTR1B, HTR1F and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%almotriptan malate%" OR LOWER(tradeNames_string) LIKE "%almotriptan malate%" OR LOWER(drugSynonyms_string) LIKE "%almotriptan malate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3458', 'drugName': 'Almotriptan Malate', 'tradeNames_string': 'Almotriptan malate, Axert', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3459', 'drugName': 'Almotriptan Malate', 'tradeNames_string': 'Almotriptan malate, Axert', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3460', 'drugName': 'Almotriptan Malate', 'tradeNames_string': 'Almotriptan malate, Axert', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1344 | Q17 | What gene does the drug Seletracetam target? | The drug Seletracetam is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SV2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%seletracetam%" OR LOWER(tradeNames_string) LIKE "%seletracetam%" OR LOWER(drugSynonyms_string) LIKE "%seletracetam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5836', 'drugName': 'Seletracetam', 'tradeNames_string': '', 'drugSynonyms_string': 'Seletracetam, UCB 44212, UCB-44212', 'linkedDiseasesDrug_string': 'Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SV2A (ENSG00000159164)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.337 | Q17 | What gene does the drug Metoclopramide Hydrochloride target? | The drug Metoclopramide Hydrochloride targets 3 genes: HTR3A, HTR4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metoclopramide hydrochloride%" OR LOWER(tradeNames_string) LIKE "%metoclopramide hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%metoclopramide hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5203', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_string': '"clopra-""yellow""", Clopra, Clopra-"Yellow", Gastrese l.a., Gastrobid continus, Gastroflux, Gastromax, Gimoti, Maxolon, Maxolon sr, Metoclomex, Metoclopramide hydrochloride, Metoclopramide intensol, Metox, Metozolv odt, Metramid, Mygdalon, Parmid, Primperan, Reglan, Reglan odt', 'drugSynonyms_string': 'AHR-3070-C, Metipamid, Metoclopramide dihydrochloride monohydrate, Metoclopramide hcl monohydrate, Metoclopramide hydrochloride, Metoclopramide hydrochloride monohydrate, Metoclopramide monohydrochloride monohydrate, Metoclopramidi hydrochloridum, NSC-757117', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea And Vomiting (HP_0002017), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Vomiting (HP_0002013), Anorexia (HP_0002039), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5204', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_string': '"clopra-""yellow""", Clopra, Clopra-"Yellow", Gastrese l.a., Gastrobid continus, Gastroflux, Gastromax, Gimoti, Maxolon, Maxolon sr, Metoclomex, Metoclopramide hydrochloride, Metoclopramide intensol, Metox, Metozolv odt, Metramid, Mygdalon, Parmid, Primperan, Reglan, Reglan odt', 'drugSynonyms_string': 'AHR-3070-C, Metipamid, Metoclopramide dihydrochloride monohydrate, Metoclopramide hcl monohydrate, Metoclopramide hydrochloride, Metoclopramide hydrochloride monohydrate, Metoclopramide monohydrochloride monohydrate, Metoclopramidi hydrochloridum, NSC-757117', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea And Vomiting (HP_0002017), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Vomiting (HP_0002013), Anorexia (HP_0002039), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5205', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_string': '"clopra-""yellow""", Clopra, Clopra-"Yellow", Gastrese l.a., Gastrobid continus, Gastroflux, Gastromax, Gimoti, Maxolon, Maxolon sr, Metoclomex, Metoclopramide hydrochloride, Metoclopramide intensol, Metox, Metozolv odt, Metramid, Mygdalon, Parmid, Primperan, Reglan, Reglan odt', 'drugSynonyms_string': 'AHR-3070-C, Metipamid, Metoclopramide dihydrochloride monohydrate, Metoclopramide hcl monohydrate, Metoclopramide hydrochloride, Metoclopramide hydrochloride monohydrate, Metoclopramide monohydrochloride monohydrate, Metoclopramidi hydrochloridum, NSC-757117', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea And Vomiting (HP_0002017), Kidney Failure (EFO_1002048), Post Operative Nausea And Vomiting (EFO_0004888), Vomiting (HP_0002013), Anorexia (HP_0002039), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), HTR3A (ENSG00000166736), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1284 | Q17 | What gene does the drug Pbf-509 target? | The drug Pbf-509 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADORA2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pbf-509%" OR LOWER(tradeNames_string) LIKE "%pbf-509%" OR LOWER(drugSynonyms_string) LIKE "%pbf-509%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5617', 'drugName': 'Pbf-509', 'tradeNames_string': '', 'drugSynonyms_string': 'Pbf-509', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1762 | Q17 | What gene does the drug Triamcinolone Diacetate target? | The drug Triamcinolone Diacetate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%triamcinolone diacetate%" OR LOWER(tradeNames_string) LIKE "%triamcinolone diacetate%" OR LOWER(drugSynonyms_string) LIKE "%triamcinolone diacetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4745', 'drugName': 'Triamcinolone Diacetate', 'tradeNames_string': 'Aristocort, Kenacort, Triamcinolone diacetate', 'drugSynonyms_string': 'Aristocort forte, NSC-757356, Orion, Polcortolon, Tedarol, Triamcinolone 16,21-diacetate, Triamcinolone diacetate', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Nasal Congestion (HP_0001742)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1459 | Q17 | What gene does the drug Solifenacin Succinate target? | The drug Solifenacin Succinate targets 2 genes: CHRM2 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%solifenacin succinate%" OR LOWER(tradeNames_string) LIKE "%solifenacin succinate%" OR LOWER(drugSynonyms_string) LIKE "%solifenacin succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1607', 'drugName': 'Solifenacin Succinate', 'tradeNames_string': 'Solifenacin succinate, Vesicare, Vesicare ls', 'drugSynonyms_string': 'Solifenacin succinate, YM-67905, YM-905, YM67905, YM905', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Benign Prostatic Hyperplasia (EFO_0000284), Urgency Urinary Incontinence (EFO_0006865)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1608', 'drugName': 'Solifenacin Succinate', 'tradeNames_string': 'Solifenacin succinate, Vesicare, Vesicare ls', 'drugSynonyms_string': 'Solifenacin succinate, YM-67905, YM-905, YM67905, YM905', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Benign Prostatic Hyperplasia (EFO_0000284), Urgency Urinary Incontinence (EFO_0006865)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM2 (ENSG00000181072), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.823 | Q17 | What gene does the drug Gsk-249320 target? | The drug Gsk-249320 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MAG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gsk-249320%" OR LOWER(tradeNames_string) LIKE "%gsk-249320%" OR LOWER(drugSynonyms_string) LIKE "%gsk-249320%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2468', 'drugName': 'Gsk-249320', 'tradeNames_string': '', 'drugSynonyms_string': 'GSK-249320, Gsk-249320', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAG (ENSG00000105695)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1114 | Q17 | What gene does the drug Pyridostigmine target? | The drug Pyridostigmine targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pyridostigmine%" OR LOWER(tradeNames_string) LIKE "%pyridostigmine%" OR LOWER(drugSynonyms_string) LIKE "%pyridostigmine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_516', 'drugName': 'Pyridostigmine', 'tradeNames_string': '', 'drugSynonyms_string': 'Mestinon, Pyridostigmine, Pyridostigmine cation, Pyridostigmine ion, Regonol', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Orthostatic Hypotension (EFO_0005252), Hiv Infection (EFO_0000764), Spinal Muscular Atrophy, Type Iii (MONDO_0009672), Heart Failure (EFO_0003144), Covid-19 (MONDO_0100096), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Parkinson Disease (MONDO_0005180), Fibromyalgia (EFO_0005687), Hypotension (EFO_0005251), Myasthenia Gravis (EFO_0004991), Proximal Spinal Muscular Atrophy Type 3 (Orphanet_83419), Ileus (MONDO_0004567)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5554', 'drugName': 'Pyridostigmine Bromide', 'tradeNames_string': 'Kalymin, Mestinon, Mestinon 10, Mestinon ret, Pyridostigmine bromide, Regonal, Regonol', 'drugSynonyms_string': 'Kalimin, Kalymin, NSC-679759, NSC-758435, Pyridostigmine Bromide, Pyridostigmine bromide, Pyridostigmini bromidum, RO-1-5130', 'linkedDiseasesDrug_string': 'Orthostatic Hypotension (EFO_0005252), Spinal Muscular Atrophy, Type Iii (MONDO_0009672), Heart Failure (EFO_0003144), Covid-19 (MONDO_0100096), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Parkinson Disease (MONDO_0005180), Hypotension (EFO_0005251), Myasthenia Gravis (EFO_0004991), Ileus (MONDO_0004567)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1524 | Q17 | What gene does the drug Esketamine Hydrochloride target? | The drug Esketamine Hydrochloride targets 7 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, GRIN3B, GRIN1 and GRIN2C. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%esketamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%esketamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%esketamine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_817', 'drugName': 'Esketamine Hydrochloride', 'tradeNames_string': 'Spravato', 'drugSynonyms_string': 'AM-101, Esketamine hydrochloride, Ketamine hydrochloride, (s)-, Ketamine hydrochloride, s-, Ketanest s', 'linkedDiseasesDrug_string': 'Tinnitus (HP_0000360), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Pain (EFO_0003843)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1941 | Q17 | What gene does the drug Fgfr Inhibitor Debio 1347 target? | The drug Fgfr Inhibitor Debio 1347 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: FGFR2, FGFR1 and FGFR3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fgfr inhibitor debio 1347%" OR LOWER(tradeNames_string) LIKE "%fgfr inhibitor debio 1347%" OR LOWER(drugSynonyms_string) LIKE "%fgfr inhibitor debio 1347%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1253', 'drugName': 'Fgfr Inhibitor Debio 1347', 'tradeNames_string': '', 'drugSynonyms_string': 'Fgfr inhibitor debio 1347', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1254', 'drugName': 'Fgfr Inhibitor Debio 1347', 'tradeNames_string': '', 'drugSynonyms_string': 'Fgfr inhibitor debio 1347', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1255', 'drugName': 'Fgfr Inhibitor Debio 1347', 'tradeNames_string': '', 'drugSynonyms_string': 'Fgfr inhibitor debio 1347', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1616 | Q17 | What gene does the drug Evt401 target? | The drug Evt401 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene P2RX7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%evt401%" OR LOWER(tradeNames_string) LIKE "%evt401%" OR LOWER(drugSynonyms_string) LIKE "%evt401%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5098', 'drugName': 'Evt401', 'tradeNames_string': '', 'drugSynonyms_string': 'Evt401', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'P2RX7 (ENSG00000089041)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1898 | Q17 | What gene does the drug Choline Fenofibrate target? | The drug Choline Fenofibrate targets the gene PPARA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%choline fenofibrate%" OR LOWER(tradeNames_string) LIKE "%choline fenofibrate%" OR LOWER(drugSynonyms_string) LIKE "%choline fenofibrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4196', 'drugName': 'Choline Fenofibrate', 'tradeNames_string': 'Trilipix', 'drugSynonyms_string': 'ABT-335, Choline fenofibrate, Fenofibric acid choline salt', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Combined Hyperlipidemia (Orphanet_79211), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Disorder Of Lipid Metabolism (Orphanet_309005)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.918 | Q17 | What gene does the drug Travoprost target? | The drug Travoprost targets the gene PTGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%travoprost%" OR LOWER(tradeNames_string) LIKE "%travoprost%" OR LOWER(drugSynonyms_string) LIKE "%travoprost%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3870', 'drugName': 'Travoprost', 'tradeNames_string': 'Izba, Travatan, Travatan z, Travoprost', 'drugSynonyms_string': 'AL-6221, NSC-760366, Otx-tp, Travoprost', 'linkedDiseasesDrug_string': 'Exfoliation Syndrome (EFO_0004235), Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1930 | Q17 | What gene does the drug Dilevalol target? | The drug Dilevalol targets 3 genes: ADRB3, ADRB1 and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dilevalol%" OR LOWER(tradeNames_string) LIKE "%dilevalol%" OR LOWER(drugSynonyms_string) LIKE "%dilevalol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6355', 'drugName': 'Dilevalol', 'tradeNames_string': '', 'drugSynonyms_string': '(r,r)-labetalol, Dilevalol, Labetalol (r,r)-form', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6354', 'drugName': 'Dilevalol', 'tradeNames_string': '', 'drugSynonyms_string': '(r,r)-labetalol, Dilevalol, Labetalol (r,r)-form', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3365', 'drugName': 'Dilevalol Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Dilevalol hcl, Dilevalol hydrochloride, SCH 19927, SCH-19927', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3364', 'drugName': 'Dilevalol Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Dilevalol hcl, Dilevalol hydrochloride, SCH 19927, SCH-19927', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1126 | Q17 | What gene does the drug Cibinetide target? | The drug Cibinetide is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CSF2RB and EPOR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cibinetide%" OR LOWER(tradeNames_string) LIKE "%cibinetide%" OR LOWER(drugSynonyms_string) LIKE "%cibinetide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1099', 'drugName': 'Cibinetide', 'tradeNames_string': '', 'drugSynonyms_string': 'ARA 290, ARA-290, ARA290, Ara 290, Ara290, Cibinetide, Ph-bsp, Phbsp', 'linkedDiseasesDrug_string': 'Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EPOR (ENSG00000187266), CSF2RB (ENSG00000100368)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.332 | Q17 | What gene does the drug Hydrocortisone Butyrate target? | The drug Hydrocortisone Butyrate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydrocortisone butyrate%" OR LOWER(tradeNames_string) LIKE "%hydrocortisone butyrate%" OR LOWER(drugSynonyms_string) LIKE "%hydrocortisone butyrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3811', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_string': 'Hydrocortisone butyrate, Locoid, Locoid c, Locoid crelo, Locoid lipocream', 'drugSynonyms_string': 'Cortisol 17-butyrate, Hydrocortisone 17-butyrate, Hydrocortisone butyrate, Hydrocortisone-17-butyrate, NSC-758433', 'linkedDiseasesDrug_string': 'Atopic Eczema (EFO_0000274), Seborrheic Dermatitis (EFO_1000764), Skin Disease (EFO_0000701), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2728', 'drugName': 'Hydrocortisone Probutate', 'tradeNames_string': 'Pandel', 'drugSynonyms_string': 'Hydrocortisone buteprate, Hydrocortisone butyrate propionate, Hydrocortisone probutat, Hydrocortisone probutate, TS 408, TS-408', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Cancer (MONDO_0004992), Ulcerative Colitis (EFO_0000729), Endocrine System Disease (EFO_0001379), Juvenile Idiopathic Arthritis (EFO_0002609), Bursitis (MONDO_0002471), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Adrenal Gland Disease (EFO_0005539), Lymphoma (EFO_0000574), Tenosynovitis (EFO_1001435), Pruritus (HP_0000989), Exanthem (EFO_1000697), Allergic Conjunctivitis (EFO_0007141), Asthma (MONDO_0004979), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Seborrheic Dermatitis (EFO_1000764), Skin Disease (EFO_0000701), Spondylitis (MONDO_0003937), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1036 | Q17 | What gene does the drug Px-12 target? | The drug Px-12 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TXN. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%px-12%" OR LOWER(tradeNames_string) LIKE "%px-12%" OR LOWER(drugSynonyms_string) LIKE "%px-12%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4688', 'drugName': 'Px-12', 'tradeNames_string': '', 'drugSynonyms_string': 'Px-12', 'linkedDiseasesDrug_string': 'Pancreatic Neoplasm (EFO_0003860)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TXN (ENSG00000136810)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.322 | Q17 | What gene does the drug Bamosiran target? | The drug Bamosiran is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bamosiran%" OR LOWER(tradeNames_string) LIKE "%bamosiran%" OR LOWER(drugSynonyms_string) LIKE "%bamosiran%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_453', 'drugName': 'Bamosiran', 'tradeNames_string': '', 'drugSynonyms_string': 'Bamosiran, SYL-040012, SYL040012, Syl040012', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1531 | Q17 | What gene does the drug Diflunisal target? | The drug Diflunisal targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diflunisal%" OR LOWER(tradeNames_string) LIKE "%diflunisal%" OR LOWER(drugSynonyms_string) LIKE "%diflunisal%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_602', 'drugName': 'Diflunisal', 'tradeNames_string': 'Diflunisal, Dolobid, Dolobid 500', 'drugSynonyms_string': 'Diflunisal, NSC-756728', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Pain (EFO_0003843), Fever (HP_0001945), Familial Amyloid Neuropathy (EFO_0004129), Rheumatoid Arthritis (EFO_0000685), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1360 | Q17 | What gene does the drug Dalfampridine target? | The drug Dalfampridine targets 40 genes: KCNB1, KCND2, KCNA7, KCNG3, KCNA4, KCNQ1, KCNQ3, KCNA1, KCNC4, KCNS1, KCNG2, KCNA6, KCNV2, KCNA5, KCNH2, KCNS3, KCNQ4, KCND3, KCNG1, KCNB2, KCNH6, KCNC3, KCNG4, KCNF1, KCNH8, KCNS2, KCNA3, KCNQ2, KCNH4, KCNA10, KCNC2, KCNC1, KCNH1, KCNH3, KCNV1, KCNQ5, KCND1, KCNA2, KCNH7 and KCNH5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dalfampridine%" OR LOWER(tradeNames_string) LIKE "%dalfampridine%" OR LOWER(drugSynonyms_string) LIKE "%dalfampridine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1734', 'drugName': 'Dalfampridine', 'tradeNames_string': 'Ampyra, Ampyra Extended Release, Fampyra, Neurelan', 'drugSynonyms_string': 'Dalfampridine, EL-970, Fampridine, Fampridine (4-aminopyridine), NSC-15041', 'linkedDiseasesDrug_string': 'Optic Neuritis (EFO_0007405), Motor Neuron Disease (EFO_0003782), Cerebral Palsy (EFO_1000632), Ischemic Stroke (HP_0002140), Multiple Sclerosis (MONDO_0005301), Prostate Disease (EFO_0009602), Stroke (EFO_0000712), Spasticity (HP_0001257), Spinal Cord Injury (EFO_1001919), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Renal Insufficiency (HP_0000083), Obstructive Sleep Apnea (EFO_0003918), Proximal Spinal Muscular Atrophy Type 3 (Orphanet_83419), Nervous System Injury (EFO_0009490), Secondary Progressive Multiple Sclerosis (EFO_0008522), Guillain-Barre Syndrome (EFO_0007292)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'numberLinkedTargets': 40}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1734 | Q17 | What gene does the drug Epoetin Beta target? | The drug Epoetin Beta targets the gene EPOR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epoetin beta%" OR LOWER(tradeNames_string) LIKE "%epoetin beta%" OR LOWER(drugSynonyms_string) LIKE "%epoetin beta%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4530', 'drugName': 'Methoxy Polyethylene Glycol-Epoetin Beta', 'tradeNames_string': 'Mircera', 'drugSynonyms_string': 'Methoxy polyethylene glycol-epoetin beta, Pegzerepoetin alfa, R-744, R744', 'linkedDiseasesDrug_string': 'Anemia (Phenotype) (EFO_0004272), Anemia (MONDO_0002280), Kidney Disease (EFO_0003086), Chronic Kidney Disease (EFO_0003884)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3185', 'drugName': 'Epoetin Beta', 'tradeNames_string': 'Marogen, Neorecormon, Neorecormon 1000, Neorecormon 10000, Neorecormon 2000, Neorecormon 20000, Neorecormon 3000, Neorecormon 30000, Neorecormon 4000, Neorecormon 500, Neorecormon 5000, Neorecormon 6000, Recormon 1000, Recormon 10000, Recormon 2000, Recormon 5000, Recormon s 1000, Recormon s 10000, Recormon s 2000, Recormon s 5000', 'drugSynonyms_string': 'BM 06.019, EPOCH, Epoetin, Epoetin beta, Erythropoietin, Erythropoietin for bioassays', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Cerebral Palsy (EFO_1000632), Hip Fracture (EFO_0003964), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Peritoneal Neoplasm (EFO_1001100), Kidney Failure (EFO_1002048), Injury (EFO_0000546), Myelodysplastic Syndrome (EFO_0000198), Foster-Kennedy Syndrome (EFO_1001330), Ovarian Cancer (MONDO_0008170), Spinal Cord Injury (EFO_1001919), Malaria (EFO_0001068), Myocardial Ischemia (EFO_1001375), Anterior Ischemic Optic Neuropathy (EFO_1000809), Optic Atrophy (MONDO_0003608), Ischemic Stroke (HP_0002140), Mood Disorder (EFO_0004247), Parkinson Disease (MONDO_0005180), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myocardial Infarction (EFO_0008583), Brain Ischemia (MONDO_0005299), Cervical Carcinoma (EFO_0001061), Necrotizing Enterocolitis (EFO_0003928), Lymphoma (EFO_0000574), Scoliosis (EFO_0004273), Diffuse Large B-Cell Lymphoma (EFO_0000403), Optic Neuritis (EFO_0007405), Premature Birth (EFO_0003917), Anemia (Phenotype) (EFO_0004272), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Subarachnoid Hemorrhage (EFO_0000713), Chronic Hepatitis C Virus Infection (EFO_0004220), Brain Injury (MONDO_0043510), Hodgkins Lymphoma (EFO_0000183), Optic Nerve Disorder (MONDO_0002135), Head And Neck Malignant Neoplasia (EFO_0006859), Chronic Kidney Disease (EFO_0003884), Asphyxia Neonatorum (EFO_1000824), Ischemia Reperfusion Injury (EFO_0002687), Amyotrophic Lateral Sclerosis (MONDO_0004976), Fallopian Tube Cancer (MONDO_0002158), Autoimmune Hepatitis (EFO_0005676), Acute Kidney Injury (HP_0001919)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.170 | Q17 | What gene does the drug Atreleuton target? | The drug Atreleuton is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ALOX5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atreleuton%" OR LOWER(tradeNames_string) LIKE "%atreleuton%" OR LOWER(drugSynonyms_string) LIKE "%atreleuton%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3626', 'drugName': 'Atreleuton', 'tradeNames_string': '', 'drugSynonyms_string': 'A-85761, A-85761.0, ABBOTT-85761, ABT-761, Atreleuton, VIA-2291', 'linkedDiseasesDrug_string': 'Acute Coronary Syndrome (EFO_0005672), Coronary Artery Disease (EFO_0001645), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ALOX5 (ENSG00000012779)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.13 | Q17 | What gene does the drug Brimonidine target? | The drug Brimonidine targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brimonidine%" OR LOWER(tradeNames_string) LIKE "%brimonidine%" OR LOWER(drugSynonyms_string) LIKE "%brimonidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4923', 'drugName': 'Brimonidine Tartrate', 'tradeNames_string': 'Alphagan, Alphagan p, Brimonidine tartrate, Brymont, Lumify, Mirvaso, Qoliana', 'drugSynonyms_string': 'AGN 190342-LF, AGN-190342-LF, AGN-190342LF, Brimonidine d-tartrate, Brimonidine tartrate, Bromoxidine tartrate, Cd-07805, OCU-300, OCU300, UK-14304-18, UK-1430418', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Flushing (HP_0031284), Rosacea (EFO_1000760), Presbyopia (MONDO_0001330), Hand-Foot Syndrome (EFO_1001893), Open-Angle Glaucoma (EFO_0004190), Hypertension (EFO_0000537), Erythema (HP_0010783), Dry Eye Syndrome (EFO_1000906), Hyperemia (EFO_0003822), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Alcohol-Related Disorders (MONDO_0021698), Corneal Edema (EFO_1000879)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5908', 'drugName': 'Brimonidine', 'tradeNames_string': '', 'drugSynonyms_string': 'AGN-190342 FREE BASE, Brimonidine, NSC-318825, UK-14304, UK-1430418 FREE BASE', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Flushing (HP_0031284), Rosacea (EFO_1000760), Presbyopia (MONDO_0001330), Diabetic Retinopathy (EFO_0003770), Open-Angle Glaucoma (EFO_0004190), Hypertension (EFO_0000537), Hand-Foot Syndrome (EFO_1001893), Erythema (HP_0010783), Dry Eye Syndrome (EFO_1000906), Ocular Hypertension (EFO_1001069), Hyperemia (EFO_0003822), Eye Allergy (EFO_0005751), Glaucoma (MONDO_0005041), Alcohol-Related Disorders (MONDO_0021698), Corneal Edema (EFO_1000879)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1927 | Q17 | What gene does the drug Nicotine target? | The drug Nicotine targets 2 genes: CHRNA4 and CHRNB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nicotine%" OR LOWER(tradeNames_string) LIKE "%nicotine%" OR LOWER(drugSynonyms_string) LIKE "%nicotine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5052', 'drugName': 'Nicotine Polacrilex', 'tradeNames_string': 'Commit, Nicorette, Nicorette (mint), Nicotine polacrilex, Thrive', 'drugSynonyms_string': 'Nicotine polacrilex', 'linkedDiseasesDrug_string': 'Nicotine Dependence (EFO_0003768), Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_687', 'drugName': 'Nicotine', 'tradeNames_string': 'Habitrol, Nicabate, Nicoderm, Nicoderm cq, Nicopass, Nicopatch, Nicorette invisi, Nicotine, Nicotinell classic, Nicotinell support, Nicotinell tts 10, Nicotinell tts 20, Nicotinell tts 30, Nicotrol, Nicotrol Inhaler, Nicotrol NS, Niquitin, Niquitin clr, Niquitin minis cherry, Niquitin minis mint, Niquitin minis orange, Niquitin mint, Niquitin pre-quit, Niquitin strips mint, Prostep, Stoppers, Stubit', 'drugSynonyms_string': 'Nicotine', 'linkedDiseasesDrug_string': 'Covid-19 (MONDO_0100096), Cannabis Dependence (EFO_0007191), Post Operative Nausea And Vomiting (EFO_0004888), Injury (EFO_0000546), Aging (GO_0007568), Nicotine Dependence (EFO_0003768), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cocaine Dependence (EFO_0002610), In Situ Carcinoma (MONDO_0004647), Alcohol Drinking (EFO_0004329), Memory Impairment (EFO_0001072), Pulmonary Sarcoidosis (DOID_13406), Chronic Obstructive Pulmonary Disease (EFO_0000341), Substance Dependence (MONDO_0004938), Depressive Disorder (MONDO_0002050), Carcinoma (EFO_0000313), Cervical Cancer (MONDO_0002974), Sarcoidosis (MONDO_0019338), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Lung Cancer (MONDO_0008903), Heart Failure (EFO_0003144), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Schizophrenia (MONDO_0005090), Severe Acute Respiratory Syndrome (EFO_0000694)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_145', 'drugName': 'Altinicline', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-5-ethynylnicotine, Altinicline, SIB-1508Y, SIB-1765F', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.174 | Q17 | What gene does the drug Azd-1656 target? | The drug Azd-1656 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GCK. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azd-1656%" OR LOWER(tradeNames_string) LIKE "%azd-1656%" OR LOWER(drugSynonyms_string) LIKE "%azd-1656%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1410', 'drugName': 'Azd-1656', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD1656, Azd 1656, Azd-1656, Azd1656', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Covid-19 (MONDO_0100096), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GCK (ENSG00000106633)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.656 | Q17 | What gene does the drug Ergotamine target? | The drug Ergotamine targets 7 genes: ADRA2A, HTR1D, ADRA2C, ADRA1D, ADRA1B, ADRA2B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ergotamine%" OR LOWER(tradeNames_string) LIKE "%ergotamine%" OR LOWER(drugSynonyms_string) LIKE "%ergotamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3132', 'drugName': 'Ergotamine Tartrate', 'tradeNames_string': 'Cafergot, Ergomar, Ergostat, Femergin, Gynergen, Lingraine, Medihaler ergotamine, Migril, Wigrettes', 'drugSynonyms_string': 'Ergotamine bitartrate, Ergotamine d-tartrate, Ergotamine tartrate, Ergotamini tartras, Gotamine tartrate, NSC-41869', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_5316', 'drugName': 'Dihydroergotamine Mesylate', 'tradeNames_string': 'D.h.e. 45, Diergo, Dihydergot, Dihydroergotamine mesylate, Tonopan, Trudhesa', 'drugSynonyms_string': 'DHE-45, Dihydroergotamine Methanesulfonate, Dihydroergotamine mesilate, Dihydroergotamine mesylate, Dihydroergotamine methanesulfonate, Migranal, NSC-759848', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6027', 'drugName': 'Dihydroergotamine', 'tradeNames_string': '', 'drugSynonyms_string': '9,10-dihydroergotamine, Dihydroergotamine, MAP-0004, MAP0004, Neomigran', 'linkedDiseasesDrug_string': 'Migraine With Aura (MONDO_0005475), Migraine Disorder (MONDO_0005277), Migraine Without Aura (MONDO_0100431)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3552', 'drugName': 'Ergotamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ergotamine, Ergotamine Tartrate, NSC-95090', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Orthostatic Hypotension (EFO_0005252), Headache (HP_0002315)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_3131', 'drugName': 'Ergotamine Tartrate', 'tradeNames_string': 'Cafergot, Ergomar, Ergostat, Femergin, Gynergen, Lingraine, Medihaler ergotamine, Migril, Wigrettes', 'drugSynonyms_string': 'Ergotamine bitartrate, Ergotamine d-tartrate, Ergotamine tartrate, Ergotamini tartras, Gotamine tartrate, NSC-41869', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_3551', 'drugName': 'Ergotamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ergotamine, Ergotamine Tartrate, NSC-95090', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Orthostatic Hypotension (EFO_0005252), Headache (HP_0002315)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1062 | Q17 | What gene does the drug Taladegib target? | The drug Taladegib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SMO. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%taladegib%" OR LOWER(tradeNames_string) LIKE "%taladegib%" OR LOWER(drugSynonyms_string) LIKE "%taladegib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6003', 'drugName': 'Taladegib', 'tradeNames_string': '', 'drugSynonyms_string': 'LY-2940680, LY2940680, Taladegib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Idiopathic Pulmonary Fibrosis (EFO_0000768), Metastasis (EFO_0009708)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.263 | Q17 | What gene does the drug Remimazolam target? | The drug Remimazolam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%remimazolam%" OR LOWER(tradeNames_string) LIKE "%remimazolam%" OR LOWER(drugSynonyms_string) LIKE "%remimazolam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3380', 'drugName': 'Remimazolam', 'tradeNames_string': 'Byfavo', 'drugSynonyms_string': 'CNS 7056, CNS-7056, Cns 7056, ONO-2745, Remimazolam', 'linkedDiseasesDrug_string': 'Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Liver Disease (EFO_0001421), Pain (EFO_0003843), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_1800', 'drugName': 'Remimazolam Besylate', 'tradeNames_string': 'Byfavo', 'drugSynonyms_string': 'BIPRAZINE PF, CNS 7056 besylate, CNS 7056B, CNS-7056 BESYLATE, CNS-7056B, GW-502056X, GW502056X, ONO-2745BS, ONO-IN-251, RF-10007, RF10007, Remimazolam besilate, Remimazolam besylate, SP148.5', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1427 | Q17 | What gene does the drug Neostigmine Methylsulfate target? | The drug Neostigmine Methylsulfate targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%neostigmine methylsulfate%" OR LOWER(tradeNames_string) LIKE "%neostigmine methylsulfate%" OR LOWER(drugSynonyms_string) LIKE "%neostigmine methylsulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1766', 'drugName': 'Neostigmine Methylsulfate', 'tradeNames_string': 'Bloxiverz, Neostigmine methylsulfate, Prostigmine, Robinul-neostig', 'drugSynonyms_string': 'Intrastigmina, NSC-93753, Neostigmine methyl sulfate, Neostigmine methylsulfate, Neostigmine methylsulphate, Neostigmine metilsulfate, Neostigmini metilsulfas, Syntostigmin', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Snoring (HP_0025267)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1582 | Q17 | What gene does the drug Lanabecestat target? | The drug Lanabecestat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene BACE1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lanabecestat%" OR LOWER(tradeNames_string) LIKE "%lanabecestat%" OR LOWER(drugSynonyms_string) LIKE "%lanabecestat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5309', 'drugName': 'Lanabecestat', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD-3293, AZD3293, LY-3314814, LY3314814, Lanabecestat', 'linkedDiseasesDrug_string': 'Liver Disease (EFO_0001421), Alzheimer Disease (MONDO_0004975), Renal Insufficiency (HP_0000083)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'BACE1 (ENSG00000186318)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.